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THE N-TERMINAL METHYLTRANSFERASE HOMOLOGS NRMT1 AND 
NRMT2 EXHIBIT NOVEL REGULATION OF ACTIVITY THROUGH 
HETEROTRIMER FORMATION 
 
Jon David Faughn 
 
June 26, 2018 
 
Protein, DNA, and RNA methyltransferases have an ever-expanding list of novel 
substrates and catalytic activities.  Even within families and between homologs, it 
is becoming clear the intricacies of methyltransferase specificity and regulation 
are far more diverse than originally thought.  In addition to specific substrates 
and distinct methylation levels, methyltransferase activity can be altered through 
formation of complexes with close homologs.  This work involves the N-terminal 
methyltransferase homologs NRMT1 and NRMT2.  NRMT1 is a ubiquitously 
expressed distributive trimethylase. NRMT2 is a monomethylase expressed at 
low levels and in a tissue-specific manner.  They are both nuclear 
methyltransferases with overlapping target consensus sequences but have 
distinct enzymatic activities and tissue expression patterns.  Co-expression of 
NRMT1 with NRMT2 increases the trimethylation activity of NRMT1, and here I 
aim to understand how this occurs.  I used analytical ultracentrifugation to show 
that while NRMT1 primarily exists as a dimer and NRMT2 as a monomer, when 
co-expressed they form a heterotrimer.  I used co-immunoprecipitation and 
molecular modeling to demonstrate in vivo binding and map areas of interaction. 
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While overexpression of NRMT2 increased the half-life of NRMT1, the reciprocal 
experiment did not produce the same results, indicating that NRMT2 may be 
increasing NRMT1 activity via increase the stability of the enzyme.  Accordingly, 
the catalytic activity of NRMT2 is not needed to increase NRMT1 activity or 
increase its affinity for less preferred substrates.  Additionally, monomethylation 
could not rescue phenotypes seen with loss of trimethylation. Taken together, 
these data support a model where NRMT2 expression activates NRMT1 activity, 
not through a catalytic change, but by increasing the stability and substrate 
affinity of NRMT1.
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A WORLD OF METHYLATION 
Types of Cellular Methylation 
As the study of genetics progressed beyond Mendel’s classic experiments 
using plant hybrides, it became clear that the central dogma of molecular biology 
was not a robust explanation for who we are. The knowledge that every cell in an 
organism shares the same genetic information, though they can become 
functionally and morphologically distinct, led to the idea that DNA sequence 
alone cannot control all hereditary traits and gave rise to what would eventually 
become the field of epigenetics. (Esteller 2007). Initially, epigenetics referred to 
modifications to DNA that did not involve changes in the DNA sequence. These 
modifications influenced the association of DNA with various regulatory proteins, 
with the most well-characterized of these being methylation of CpG-rich regions 
of DNA. These areas, termed CpG islands, are generally found in upstream 
regulatory sites of genes, and in their unmethylated state allow the gene to be 
transcribed after association with the necessary transcription factors (Holliday 
and Pugh). However, genes that need to be expressed dynamically or in a 
tissue-specific manner have promoter regions that are heavily methylated. This 
adds an extra layer of control over DNA sequence for establishing distinct cellular 
phenotypes. 
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DNA methylation also allows for modification of gene control over an 
organism’s lifespan.  Studies looking at phenotypic differences between 
monozygotic twins (twins sharing a common genotype) found disease 
susceptibility and morphological differences between all sets of twins.  However, 
in examining global and locus-specific DNA methylation, twins were found to be 
epigenetically indistinguishable early in life. Only in examining older twin sets did 
it become evident that there were vast alterations in the amount and distribution 
of promoter methylation between genetically identical pairs (Fraga et al. 2005). 
This was striking evidence that dynamic changes in protein expression can give 
rise to individual phenotypes that are regulated by mechanisms outside heritable 
genotype, such as DNA methylation. Furthermore, these mechanisms can 
change over time and in response to environmental stimuli.   
 It soon became clear that DNA methylation was not the only type of 
methylation affecting the epigenetic landscape.  In 1964, while using puromycin 
to inhibit protein translation, it was noted that amino acid incorporation into 
histone proteins is blocked but the addition of methyl groups is not (Allfrey et al., 
1964). This provided evidence of an enzyme responsible for post-translationally 
methylating histone proteins. The enzyme responsible, Protein Methylase I, was 
partially purified and found to use S-adenosyl-L-methionine (SAM) as a methyl 
donor to target the guanidino group of arginine residues.  Around 70% of the 
radio-labeled SAM was found to be incorporated into histones, and it was 
concluded these were the primary methyl acceptor proteins. Soon after, Protein 
Methyltransferase II, targeting the carboxyl groups of proteins, and Protein 
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Methyltransferase III, targeting the ε -amino groups of lysine, were discovered 
and purified. The discovery of Protein Methyltransferase III also speculated on 
the existence of multiple enzymes for mono-, di-, and trimethylation (Kim & Paik, 
1965; Paik & Kim, 1968; Kim & Paik, 1970; Paik & Kim, 1970). 
 While the number of post-translational modifications and their associated 
enzymes continued to grow, it wasn’t until the 1990s that genetic and chromatin 
biology experimental techniques had advanced enough to associate functional 
roles for protein methylation. The demonstration that arginine methylation, 
carried out by the yeast homolog of human protein arginine N-methyltransferase 
1 (PRMT1), is necessary for the export of nuclear ribonucleoproteins uncovered 
the first physiological role for post-translational protein methylation (Shen et al., 
1998). Soon after, a role for eukaryotic histone lysine methylation was 
discovered. Methylation of lysine 4 of histone 3 (H3K4) is highly conserved and 
plays a necessary roll in the facilitation of transcription (Strahl et al., 1999). 
Within the coming years, the histone-targeting SET domain-containing family of 
protein methyltransferases would be discovered. As the size of the SET family 
increased, it became evident that histones were not the only targeted substrates, 
but non-histones as well, controlling signaling pathways, transcription factors, 
and tumor suppressors (Herz et al., 2013). The SET classification currently has 
56 family members that methylate a variety of targets, and in many of which 
mutations have been shown to coincide with various diseases and cancer (Albert 
& Helin, 2010).  
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 The discovery of multiple methyltransferase families, as well as 
associations with other post-translational modifications (PTMs) such as 
acetylation, phosphorylation, ADP-ribosylation, ubiquitination, and citrullination of 
histones gave rise to the concept these chemical marks may encode a kind of 
“language,” eventually termed the histone code (Strahl & Allis, 2000). The 
histone code specifies the pattern of these PTMs on histones encodes for 
transcriptional activation or repression, with histone methylation contributing to 
the heritable nature of the code (Strahl & Allis, 2000).  To add a level of 
complexity, histone methylation can promote transcriptional activation or 
repression depending on which residue it occurs.  Histone H3 lysine 4 
trimethylation (H3me3K4) is a classic marker of transcriptional activation, while 
histone H3 lysine 9 trimethylation (H3me3K9) is a classic marker of 
transcriptional repression (Bernstein et al., 2002). The level of methylation on 
each individual residue can also have distinct effects.  For example, 
monomethylated histone 3 lysine 27 (H3meK27) promotes transcriptional 
activation, while the di- or trimethylated residue (H3me2/3K27) is repressive.  
Histone 3 lysine 79 mono- and dimethylation (H3me1/2K79) also promote 
transcriptional activation, while trimethylation can cause either activation or 
repression dependent upon other PTMs nearby (Rosenfeld et al., 2009; Barski et 
al., 2007; Steger et al., 2008).  
Epigenetic modification of RNA nucleotides is the most recent discovery 
and includes modification of the four common nucleotide bases to over a 
hundred chemically distinct modified structures that are present in all eukaryotic 
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species (Cantara et al., 2011). These modifications allow for intricate control over 
RNA-specific cellular processes and RNA-mediated structural support. It was 
long thought that RNA modifications were static, due to the covalent nature of the 
bonds (He, 2010).  However, within the last 5-10 years, the most common 
epigenetic mark among mammalian RNA, N6-methyladenosine, has been 
demonstrated to be dynamic and reversible (Jia et al., 2011; Zheng et al., 2013).  
N6-methyladenosine has ubiquitous tissue distribution and broad 
implications in post-transcriptional gene regulation. Using m6A RNA 
immunoprecipitation, followed by high-throughput sequencing, m6A has been 
identified in more than 7,000 human mRNAs and 300 non-coding RNA 
transcripts. It has also been found in micro-RNAs and long non-coding RNA 
transcripts (Dominissini et al., 2012; Meyer et al., 2012, Fu et al., 2014). m6A 
methylation is ubiquitously involved across the life cycle of RNA, as well as 
different tissues and cell lines. m6A methylation directly modifies RNA structure, 
subsequently improving accessibility for a number of RNA-binding proteins (Lue, 
et al., 2015). It is also involved in pre-mRNA splicing, pri-miRNA processing, 
nuclear export, modulation of translation, and RNA degradation (Pan et al., 
2018).  The misregulation of m6A RNA methylation is implicated in both solid and 
hematopoietic tumor development, continued oncogenesis, and tumor metastasis 
(Vu et al., 2017; Cai et al., 2018; Cui et al., 2017; Yuan et al., 2014; Chen et al 
2017). Recently, m6A RNA methylation has been also linked to pluripotency of 
cancer stem cells; small subsets of neoplastic cells within tumors with stem-like 
capacity of self-renewal, survival, and the ability to reemerge as drivers of 
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tumorigenesis even years after detection of a primary tumor (Vu et al., 2017; 
Kreso & Dick, 2014).    
Methyltransferase families 
 The addition of a methyl group can be accomplished by a variety of 
reactions onto hundreds of different substrates. However, the enzymes that 
catalyze these reactions are found in a relatively small number of structural 
arrangements and with conserved primary structures that allow for their 
separation into similar groups (Petrossian & Clarke, 2011). As of 2017, structural 
alignment and clustering of the catalytic domains of known methyltransferases 
result in the classification of eleven SAM-dependent and four SAM-independent 
families (Fenwick & Ealick, 2018).  SAM-dependent methyltransferases employ 
SAM as the methyl group donor to methylate target substrates, leaving the 
product S-adenosyl-homocysteine (SAH) (Cheng & Blumenthal, 1999).  SAM-
independent methyltransferases employ a variety of methyl donors, including 
tetrahydrofolate (THF), betaine, methylamine, and O6-methylguanine-DNA 
(Doukov et al., 2000; Evans et al., 2002; Moore et al., 1994; Niedzialkowska et 
al., 2016).  
Structurally, the majority of the SAM-dependent methyltransferases fall 
into the Class I (7-beta-strand) methyltransferase family. Class I 
methyltransferases are composed of alternating beta strands and alpha helices, 
typically forming a seven-stranded beta sheet with three alpha helices on each 
side (Fenwick & Ealick, 2018). The evolutionarily-conserved N-terminal side of 
the beta sheet forms the Rossman fold SAM-binding motif of each enzyme, while 
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the dynamic C-terminal side of the sheet binds the substrate. Given the number 
of possible substrates for SAM-dependent methyltransferases (nucleic acids, 
proteins, small molecules), the vast shape and structure of the C-terminal region 
isn’t surprising. (Martin & McMillan, 2002). While many of the SAM-dependent 
methyltransferases are monomers, they can also be expressed as homodimers 
and tetramers (Huang et al., 2000).  
The DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) are part 
of the Class I family and are each comprised of a large, multi-domain N-terminus 
with regulatory functions, and a catalytic C-terminus (Cheng & Blumenthal, 
2008). Each catalytic domain is comprised of a common structure consisting of a 
mixed seven-stranded beta sheet, formed by six parallel and one antiparallel 
beta strands (Cheng & Blumenthal, 2008). Additionally, six helices are folded 
around the central beta sheet. This conserved domain is implicated in both 
catalysis and cofactor binding, with a nearby nonconserved region that 
recognizes specific DNA targets (Cheng et al., 1995; Jeltsch et al., 2002; Cheng 
et al., 2008; Jurkowska, 2011). While DNMT1, DNMT3A, and DNMT3B have 
catalytic activity alone, there is a fourth DNMT, DNMT3L, that is unable to bind 
SAM and is catalytically inactive, despite sharing homology to its other family 
members (Gowher et al., 2002; Gowher et al., 2005; Kareta et al., 2006). 
DNMT3A and DNMT3L form a heterotetramer consisting of two DNMT3A and 
two DNMT3L homologs. Both enzymes contain hydrophobic interfaces 
characterized by the stacking of two phenylalanine residues, facilitating protein-
protein interactions as well as contact between DNMT3A and DNMT3L. This 
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region of contact affects the position of alpha helices in DNMT3A and is likely 
responsible for the increased interaction of the complex with target DNA, even 
though DNMT3L has no catalytic activity of its own (Jia et al., 2007; Jurkowska et 
al., 2008; Jurkowska et al., 2011).  
The first identified “writer” of m6A methylation was found to be a highly-
conserved methyltransferase enzyme, METTL3, which is also in the Class I 
family (Bokar et al., 1997). After its identification as an RNA methyltransferase, it 
was shown that its catalytic activity was also dependent on interaction with an 
inactive homolog, METTL14 (Bokar et al., 1997; Bujnicki, 2002; Wang et al., 
2014; Ping et al., 2014). Both METTL3 and METTL14 are SAM-dependent 
enzymes, and subsequent investigation has shown that this heterodimer complex 
and its associated interaction with Wilms’ tumor 1-associating protein (WTAP) 
are implicated in increased substrate selectivity and tighter control of levels of 
target methylation (Ping et al., 2014). Knocking down the METTL3-METTL14-
WTAP complex results in longer half-lives and more abundant distribution of their 
target RNAs (Ping et al., 2014). This is indicative that m6A methylation is 
functioning to repress the transcription of target genes (Alexandrov et al., 2002; 
Ozanick et al., 2005; Leulliot et al., 2008).  Additionally, knockdown of WTAP 
results in mislocalization of METTL3 and METTL14 to their associated mRNAs, 
indicating an interaction among each of the components is crucial for proper 
substrate targeting (Ping et al., 2014).  
The methylation activity of the METTL3-METTL14-WTAP complex is 
greater than that METTL3 and METTL14 individually (note: WTAP does not have 
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methyltransferase activity itself) (Liu et al., 2014). Crystallization of the complex 
revealed METTL3-METTL14 methyltransferase domains that are highly similar to 
other Rossman fold-containing methyltransferases, with each comprising a 
central, curved, eight-stranded beta sheet flanked by four alpha helices. 
Dimerization of the complex was found to be governed by extensive hydrogen 
bonding interactions and hydrophobic contacts. Interestingly, though both 
METTL3 and METTL14 have low catalytic activity individually, steric hindrance 
and occlusion by METTL3 side chains prevented the binding of SAM to the 
catalytic site of METTL14 when in complex (Sledz & Jinek, 2016; Wang et al., 
2016). Knockout of METTL3 or METTL14, individually, has been demonstrated to 
abrogate all substrate binding and subsequent m6A mRNA methylation in mouse 
embryonic stem cells (Geula et al., 2015). This is indicative that METTL14 is 
likely facilitating an increase in integrity and substrate targeting of the complex, 
though not playing a role in catalysis.  
The SPOUT family of methyltransferases comprises the second most 
abundant SAM-dependent class of methyltransferases and is characterized by a 
six-stranded parallel beta sheet surrounded by seven alpha helices, with the first 
three strands forming the classic Rossman fold (Anantharaman, 2002; Fenwick & 
Ealick, 2018). As a homodimer, the C-terminus comprises several conserved 
catalytic residues, and the active site is located near the surface and comprises 
residues of both monomers (Anantharaman et al., 2002; Shubert 2003; Michel et 
al., 2003). SPOUT family members share a common topological feature of a 
deep trefoil knot in the catalytic domain, responsible for binding S-adenosyl-
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methionine (Lim, et al., 2003). SPOUT-family methyltransferases target tRNA for 
methylation, which is associated with a number of molecular functions, including 
promotion of secondary structure and thermodynamic stability of tRNA, 
protection from degradation, and a variety of effects on translation (Voigts-
Hoffman et al., 2007; Edmonds et al., 1991; Alexandrov et al., 2006, Björk et al., 
2001).  
 The other major SAM-dependent family of methyltransferases is the 
Su(var), Enhancer of zeste, Trithorax (SET) family.  SET-domain 
methyltransferases function primarily in large macromoleculer complexes. Each 
SET-domain methylatransferase contains eight curved beta strands that form 
three small sheets, with the C-terminus forming a knot-like structure below the 
surface loop. Unique to the SET family, a set of highly conserved residues form a 
triangular zinc cluster that is necessary for cofactor binding and transfer of the 
methyl group (Schultz et al, 1998; Zhang et al., 2002). Substrate recognition by 
the SET domain is governed by the N- and C-termini, which are near the active 
site, and by recognition of regions far from the active site during incorporation 
with other large macromolecular complexes (Trieval et al., 2002). Species of SET 
proteins can mono-, di-, or trimethylate, and are generally classified by the lysine 






 Chemical modifications to nucleotides or proteins are only as effective as 
their ability to be recognized. Methylation “readers” encompass a number of 
proteins whose actions are dependent on the recognition of this methylation 
state. The inability or aberrant recognition of this epigenetic state is implicated in 
developmental defects and various cancers, implicating methyl-readers as critical 
factors in health and disease (Wang & Allis, 2009; Chi et al., 2010).   
 A number of methylation readers have been described (Taverna et al., 
2007; Musselman et al., 2012; Patel et al., 2013), with the largest family of 
readers making up the plant homeodomain (PHD) finger-containing proteins. The 
PHD finger is a globular protein consisting of two beta-sheets and an alpha helix, 
featuring conserved cysteine and histidine residues that function to coordinate 
two Zn2+ ions (Pascual et al., 2000). The PHD finger family of readers recognizes 
multiple levels of methylated lysine and unmodified lysine residues on histone 
tails (Musselman & Kutateladze, 2011; Sanchez & Zhou, 2011). As with many 
readers of methylation, the recognition of the substrate is governed by a 
structurally-conserved region of the PHD finger consisting of two to four aromatic 
residues, forming an aromatic cage. The aromatic rings are positioned in such a 
way as to cation-pi, hydrophobic, and van der Waals contacts with the 
trimethylated lysine residue (Mussleman 2009, 2011).  
 The so-called “Royal Family” methylation readers include the three beta-
strand core regions of chromodomains, Tudor, malignant brain tumor (MBT) 
repeats, and conserved proline and tryptophan (PWWP) domains. Each of these 
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share significant sequence similarities and have evolved from a larger 
homologous superfamily (Maurer-Stroh et al., 2003). The Tudor and 
chromodomains also share equivalent recognition regions, with both binding 
methylated peptides using equivalent amino acid positions and structure 
(Maurer-Stroh, et al., 2003). The PWWP domain contains a five beta-stranded 
structure and likely is a result of divergent evolution from the same superfamily 
from which the Tudor and chromodomains evolved (Maurer-Stroh et al., 2003). 
DNMT3B contains a PWWP domain that contains a basic surface region and is 
responsible for DNA binding, although these basic residues are not evolutionarily 
conserved (Maurer-Stroh et al., 2003. As such, it remains unclear if all PWWP-
containing proteins exclusively bind DNA. Interestingly, though the PWWP 
domain of DNMT3B binds DNA, it has not been demonstrated as a necessary 
requirement for CpG methylation (Qui, et al., 2002).  
The MBP family of methyl readers have a general preference for binding 
mono- or dimethylated peptides over trimethylated peptides (Kim et al., 2006). 
This is a result of steric clashes within the aromatic cage of MPB repeats with 
trimethylated (and unmodified) peptides. This is due to hydrogen bond formation 
between the methylammonium proton and carboxylate acid residue of an 
aspartic acid residue lining the aromatic cage pocket (Li et al., 2007). 
Additionally, the other methylammonium proton of the substrate is hydrogen 
bonded to a water molecule that is held in place by the nearby main-chain 
residues (Li et al., 2007).  This aromatic cage recognition motif is shared among 
all members of the “royal family” readers. The multiple binding pockets of MBP 
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domains give precise control over which level of methyl mark is bound, furthering 
the evidence that tight control of chromatin regulation by histone PTMs isn’t only 
controlled by whether or not a methyl group is present, but to the level at which it 
is present.  
 
Functions for different levels of methylation 
 In 1971, it was noted that mono- and dimethylated arginine had distinctly 
different levels of resistance to tryptic attack, and as such, proposed that specific 
levels of methylation could govern association with nearby proteins via an 
increasing hydrophobic characteristic of the guanidine group that is promoted by 
increasing methylation (Brostoff & Eylar, 1971). However, it wasn’t until the 
discovery of the histone code that distinct functions for distinct levels of 
methylation became clear.  
The emergence of the concept of the histone code described the idea that 
the sequence of PTMs on histone proteins could form a language governing the 
recruitment of chromatin remodelers and subsequent expression and repression 
of genes (Strahl & Allis, 2000).  As reader proteins were discovered and 
characterized, this “language” evolved and control of gene expression by PTMs 
was found to be increasingly complex (Patel & Wang, 2013).  An additional layer 
of complexity was illuminated when it was found that reader proteins not only 
recognize if lysine and arginine residues in histones are methylated but also to 
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what degree the methyl marks are deposited (mono-, di-, or trimethylation for 
lysine and mono- or dimethylation for arginine) (Kim et al., 2006).  
Proteome diversity is not only governed by the presence or absence of a 
methyl group, but also to what extent a residue is methylated. Different 
methylation states will recruit different reader proteins, ultimately facilitating 
different protein-protein interactions, or in the case of histone proteins, differential 
gene expression (Li et al., 2006). A number of factors are involved in the 
recognition of different methyl states, though the majority involve the aromatic 
cage present in all methyllysine reader complexes (Beaver & Waters, 2016). The 
shape, depth, and composition of the binding pocket, number of cation-pi 
interactions among the aromatic rings and polarized methyl groups, and 
presence of negatively charged side chains and hydrogen bond acceptors all 
contribute to the selectivity of distinct levels of methylation (Hughes et al., 2007; 
Ma & Dougherty 1997; Guo et al., 2009; Botuyan et al., 2006; Jacobs & 
Khorasaniz 2002; Llin et al., 2006; Taverna et al., 2007). Additionally, single 
amino acid substitutions within these chromodomains facilitate enough alteration 
of the binding pocket to differentiate between di-, and trimethylysine residues 
(Eisert & Waters, 2011).  
 
Demethylases 
The ability to read PTMs at the level of methylation led to the idea that not 
only is methylation deposition tightly regulated, but its removal may be as well. It 
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was long suspected that histone methylation was an irreversible mark, because 
the half-lives of histones and the methylated lysine residues associated with 
them had been shown to be the same (Byvoet, 1972).  However, rapid activation 
and repression of gene expression isn’t compatible with the idea that the 
methylated residues must degrade at the same rate as the histone itself 
(Chinenov, 2002), and it was thought that a histone demethylase must exist.  A 
number of demethylating enzymes, with various catalytic methodologies had 
been described, but their characterization was limited by the inability to pinpoint 
their activity to a specific target or show direct activity against amino acid side 
chains within proteins (Kim et al., 1964; Paik & Kim 1973; Paik & Kim, 1974; 
Khanna & Jorns, 2001; Chinenov 2002).  
The first protein lysine-specific demethylase (or “eraser” protein) was 
characterized in 2004 (Shi et al., 2004). Lysine-specific demethylase-1 (LSD1) is 
an evolutionarily conserved amine oxidase that preferentially targets methylated 
H3K4 for demethylation via an oxidation reaction (Shi et al., 2004). Similar to the 
substrate specificity of its methyltransferase counterparts, LSD1 is able to 
distinguish between methylated lysine on H3K4 and H3K9 (Shi et al., 2004). 
Additionally, it is able to discriminate between di- and trimethylation of H3K4, as 
trimethylated variants of the same residue are unable to be demethylated (Shi et 
al., 2004; Metzger et al., 2005). Soon after the discovery of LSD1, a second 
demethylase was discovered, JmjC domain-containing histone demethylase 1 
(JHDM1). JHDM1 specifically targets dimethylated H3K36 for demethylation via a 
hydroxylation-mediated mechanism (Tsukada et al., 2006).  
	 16	
Whether it was steric hindrance between the demethylase binding pocket 
and lysine trimethylation (as the case for JHDM1) or the requirement of a 
protonated nitrogen (as in the case for LSD1), the discovery of a demethylase 
capable of removing a trimethylation mark remained elusive.  The first family of 
demethylases capable of removing trimethylation, JMJD2, was found using a 
candidate gene screen (Tsukada et al., 2006).  Twenty-eight members of the 
JmjC family were assayed for the ability to use a hydroxylation-mediated 
mechanism to demethylate trimethylated histone lysines (Cho et al., 2012). 
JMJD2A and JMJD2C were shown to catalyze demethylation of trimethylated 
H3K9 and trimethylated H3K36. However, while they could both convert 
trimethylation to dimethylation, neither could convert dimethylation to 
monomethylation (Whetstine et al., 2006).  The only JMJD2 family member 
capable of converting H3me3K9 to H3me1K9 was JMJD2D (Toyokawa et al, 
2011). While the JMJD2 family members all were specific for methylated lysine 
residues, they differed in the degree of methylation they could remove, indicating 
an additional level of demethylation regulation and reinforcing the notion that 
different levels of methylation encode different functional readouts (Whetstine, et 
al., 2006, Vakoc et al., 2005; Krogan et al., 2006).  
 
Physiological impact of aberrant protein & DNA methylation 
As described above, the dynamics of protein methylation are incredibly 
precise and tightly controlled. Perturbing this system, whether it be through mis-
writing, mis-reading, or mis-erasing of methylation marks has been shown to 
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facilitate oncogenesis and the progression of a variety of other diseases.  The 
overall misregulation of DNA methylation has emerged as a fundamental part of 
chromosomal stability, proper gene expression, genome imprinting, and 
transcriptional silencing of foreign DNA fragments (Levin & Moran, 2011; Peters 
2014; Jaenisch & Bird; 2003). Inappropriately methylated DNA can interact with 
other genomic elements, such as histone modifications, and can similarly be 
involved in the incorrect positioning of histones during tumor initiation and 
oncogenesis (Esteller, 2007; Feinberg et al; 2006). Oftentimes, this misregulation 
of DNA methylation is found in common patterns among tumor- and stage-
specific variants cancers and can serve as a useful biomarker for clinical 
diagnostics (Cancer Genome Atlas Network, 2008).   
Cancer-related inhibition of DNA methylation has become a common 
target of chemotherapeutic development over the last 15 years. Small-molecule 
inhibitors like azacitidine target DNA methyltransferases by functioning as a 
nucleoside cytidine and incorporating into RNA to lead to inhibition of the 
production of the protein (Cihak, 1974). Azacitidine has shown efficacy in treating 
myelodysplastic syndrome and cutaneous T-cell lymphoma, as well as moderate 
success in acute myelogenous leukemia (Cowan et al., 2010). In addition to a 
cancer therapeutic, azacytidine has been in successful in the treatment of HIV 
and human T-lymphotropic virus (Dapp et al., 2009; Diamantopoulous et al., 
2012).  
More recently, combinatorial therapies using monoclonal antibodies 
targeting immune checkpoint factors such as programmed cell death protein-1/2 
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(PD-1, PD-2) or cytotoxic T lymphocyte antigen-4 (CTLA-4) receptors and DNA 
methyltransferase inhibitors have been explored in order to increase 
immunotherapy responses and decrease the ability for malignancies to evade the 
host immune system (Mazzone et al., 2017). Increased H3K27 trimethylation 
(H3K27me3), facilitated by Enhancer of Zeste-2 (EZH2) can lead to 
differentiation and increased plasticity of CD4+ T-cells, decreasing 
immunosurveillance and the ability to distinguish tumor cells from non-tumor cells 
(Tumes et al., 2013). Pre-clinical studies have shown combinatorial therapy with 
anti-PD-1 and anti-CTL-4 antibodies and azacytidine to be more efficacious in 
eradicating metastatic tumors from melanoma in mice versus treatment with both 
immunotherapies alone (Kim et al., 2014).      
Mutations of the highly conserved H3K27 methyltransferase, (EZH2), the 
catalytic component of the polycomb repressor complex (PRC2), are among the 
most common driver mutations found in the progression of solid tumors 
(Varambally et al., 2002). Overexpression of EZH2 has been shown to be a 
prognostic marker for prostate cancer progression, with the lowest expression 
being associated with localized disease and highest found in metastatic tumors 
(Varambally et al., 2002; Rhodes et al., 2003, Saramaki et al., 2006; Yu et al., 
2003). A correlation between increased EZH2 expression is also found in 
invasive breast metastases versus primary and local tumors (Kleer et al., 2003).  
Additionally, recent work has found mutations in EZH2 to be associated 
with hematological disease progression (Yap et al., 2011). A subset of B-cell 
lymphoma patients feature mutations of Y641 in SET domain of the EZH2 
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complex, with the EZH2(Y641) phenotype being associated with increased levels 
of H3K27 trimethylation levels and acting as a gain-of-function mutation to 
increase histone methylation (Ciferri et al., 2012; Yap et al., 2011). Around 30% 
of germinal center B-cell type diffuse large B-cell lymphoma (DLBCL) and around 
10% of follicular lymphoma (FL) harbor this mutation (Morin et al., 2010). 
EZH2(Y641) mutants are shown to favor trimethylation over mono- or 
dimethylation, and thus accumulate an abnormal amount of trimethylated histone 
marks versus wild type (WT). This is likely associated with a structurally larger 
substrate-binding pocket formed by a mutation of the Tyr 641 residue to a 
smaller residue such as His, Asn, or Phe (Yap, 2011). Mutations in DLBCL and 
FL repress genes associated with cellular proliferation checkpoints and terminal 
differentiation (Yap et al., 2011). Normally, the expression of WT EZH2 
decreases and the expression of genes involved in terminal differentiation 
increases, as the B-cell moves away from the germ center phenotype (Yap et al., 
2011).  However, mutant EZH2 mitigates these checkpoints and results in B-cell 
hyperplasia (Yap et al., 2011). Similar to that of prostate cancer (Saramaki et al., 
2006), these epigenetic mutations are reversible in lymphoma, with suppression 
of EZH2 correlating with the reexpression of tumor suppressor genes (Beguelin, 
2013).  
In addition to misregulated histone methylation, aberrant expression of 
methyltransferases can also result in sweeping changes in the function of non-
histone oncogenes and tumor suppressors. Lysine residues on cancer-
associated transcription factors, including p53, NFkappaB, and STAT3, are 
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targeted for methylation by some of the same enzymes associated with histone 
methylation (Stark et al., 2011). The functional consequences of this methylation 
are dependent on the particular residue and degree to which it is methylated 
(Stark et al., 2011).  SMYD2, an H3K4 methyltransferase, also monomethylates 
K370 on p53, leading to transcriptional repression of certain p53 target genes 
(Huang, 2006). K370 is also a target for dimethylation, which stimulates 
interaction with the p53 coactivator 53BP1 and strongly increases p53 
expression (Huang et al., 2007). Both mono- and dimethylation are removed from 
p53 K370 by the H3K4 demethylase LSD1 (Huang, 2007). Additionally, lysine 
residues in the regulatory C-terminus of p53 are targets for the histone 
methyltransferase, Set9 (Chuikov et al., 2004) Methylation of these residues is 
associated with p53 stability and association with target genes, and a reduction 
in Set9 decreases both these phenotypes (Chuikov et al., 2004).   
Interestingly, SET9 also targets lysine residues on the p65 subunit of the 
NFκB transcription factor. Increased NFκB-associated inflammatory response 
was noted with increased SET9-dependent lysine methylation (Ea et al., 2009; 
Lu 2010). In an opposing manner, monomethylation of the RelA subunit of NFκB 
by SETD6 attenuated RelA-dependent transcription pathways, including 
inflammatory responses of immune cells (Levy et al., 2011). In addition to its role 
as an H3K27 trimethylase, a novel role for EZH2-dependent methylation of the 
STAT3 transcription factor has been elucidated. Increased tyrosine 
phosphorylation of STAT3 is associated with increased proliferation of 
glioblastoma stem-like cells, and this phosphorylation is dependent on EZH2 
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methylation. Inhibition of EZH2 reverses this phenomenon and decreases 
expression of pro-oncogenic proteins (Kim et al., 2013).  
To further illustrate the role methyltransferases play on transcription 
factors, tumor-associated proteins, and downstream cell proliferation, SMYD2-
mediated methylation of estrogen receptor alpha (ERα) attenuates recruitment to 
chromatin and prevents active transcription of target genes under an estrogen-
depleted condition (Zhang et al., 2013; Hamamoto et al., 2014). This methylation 
is diminished upon estrogen stimulation and allows for acetylation of ERα, 
increasing target gene transcription and demonstrating the crosstalk between 
PTMs and related transcriptional changes (Zhang et al., 2013). Increased 
SMYD2 expression is also found to correlate with human bladder carcinomas 
compared to non-neoplastic bladder tissue. This is due to the increased 
methylation of Rb by SMYD2, in which the methylation also accelerated 
phosphorylation of Rb, promoting cell cycle progression of cancer cells (Cho, 
2011; Carr 2011).  
Besides transcription factors, various other non-histone substrates are 
also targets for modification by methyltransferases. and the over or under-
expression of these associated enzymes can facilitate pro-tumorigenic outcomes. 
Heat-shock protein 70 (HSP70) is a highly evolutionarily conserved molecular 
chaperone, found to be non- or minimally-methylated in non-neoplastic tissues, 
with highly dimethylated variants found in a number of cancerous tissues (Cho et 
al., 2012). This is due to increased expression of the SET1D1A 
methyltransferase, which increases lysine dimethylation of HSP70 and promotes 
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a methyl-dependent association with Aurora kinase B and subsequent growth of 
cancer cells (Cho et al., 2012).  In a similar manner, HSP90 is methylated in 
much higher amounts in cancerous tissues due to increased SMYD2-dependent 
methylation, facilitating increased chaperone complex formation and accelerated 
proliferation (Hamamoto, et al., 2014).  
Elevated expression of SMYD3 is associated with colorectal, 
hepatocellular, and breast carcinomas (Hamamoto et al., 2004; Hamamoto et al., 
2006; Saddic et al., 2010; Mazur et al., 2014). SMYD3-dependent methylation of 
vascular endothelial growth factor receptor 1 (VEGFR1) on a lysine residue in its 
kinase domain increases its kinase activity and accelerates proliferation of 
carcinoma cells (Kunizaki et al., 2007). In a similar study, increased SMYD3 
expression increases methylation of MAP3K2, which promotes increased MAP 
kinase signaling and promotes the formation of Ras-driven carcinomas (Mazur et 
al., 2014). Additionally, highly methylated arginine and lysine residues of 
VEGFR2 have been shown to play a critical role in the tyrosine phosphorylation 
and activation of VEGFR2-mediated angiogenesis pathways (Hartsough et al., 
2013). Thus, alteration in histone methyltransferase expression not only affects 
transcriptional dynamics directly through chromatin architecture but also 
indirectly through regulating the function of non-histone protein targets.  It can 
also be associated with changes in additional PTMs, dramatically altering the 





Most of the literature focusing on the functional roles of protein 
methylation centers on methylation of lysine and arginine side chains.  However, 
an additional type of protein methylation, α -amino methylation of the N-terminal 
amino acid (N-terminal methylation), has also been identified. The initial reports 
of N-terminal methylation on the bacterial ribosomal proteins L16 and L33 were 
first published in 1976, and the list of N-terminally methylated substrates slowly 
expanded for the next three decades (Brosius & Chen, 1976; Chang et al., 1976; 
Wittman-Liebold et al., 1976; Stock et al., 1987). A common consensus 
sequence of Xxx-Pro-Lys (X-P-K) emerged as the number of mono-, di-, and 
trimethylated substrates grew, and it was hypothesized that an enzyme or group 
of enzymes were responsible for the recognition of this sequence and 
subsequent methylation (Stock et al., 1987).  
N-terminal RCC1 methyltransferase-1 (NRMT1), formally notated as 
METTL11A, was identified as the first N-terminal methyltransferase enzyme in 
both yeast and humans (Webb et al., 2010; Tooley et al., 2010).  As predicted, it 
is able to methylate an X-P-K consensus sequence, and database searches for 
proteins beginning with this consensus identified at least 100 putative target 
substrates (Tooley et al., 2010).  NRMT1 is a 25 kDa protein from the Class I 
family of methytransferases.  In vitro peptide methylation assays and substrate 
immunoprecipitations have recently expanded the X-P-K consensus sequence of 
NRMT1 (Petkowski, 2012).  After initiating methionine cleavage, position 1 can 
be alanine, proline, serine, glycine, or methionine. Position 2 can encompass 
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most uncharged polar or nonpolar amino acids, and position three can be either 
Lys or Arg (Petkowski, 2012). This expanded consensus sequence increases the 
number of potential NRMT1 targets to over 300, making α-N-terminal methylation 
a much more abundant modification than initially hypothesized (Petkowski, 
2012). Specificity was further characterized by showing the affinity of NRMT1 for 
its substrates is dictated by the substrate’s consensus sequence (Petkowski, 
2012). Of those already tested, NRMT1 exhibits the strongest affinity for 
substrates beginning with a P-P-K consensus or substrates that have been 
previously mono- or dimethylated (Petkowski, 2012). 
This preference for ringed prolines or pre-methylated substrates is 
predicted to result from a favorable interaction between these substrates and a 
conserved triad of aromatic residues making up the “aromatic cage” domain of 
NRMT1 (Petkowski et al., 2012).  Of note, this aromatic cage is similar to those 
seen in chromodomains that bind methylated lysine residues (Nielson et al., 
2002).  Kinetic studies using an N-terminal RCC1 peptide as substrate and/or 
specific chemical inhibitors have determined that NRMT1 works through a 
random sequential bi-bi kinetic mechanism with distributive processivity 
(Richardson et al., 2015).  Either SAM or the protein substrate can be the first to 
bind NRMT1, and methyl groups are distributed one at a time versus en masse 
(Richardson et al., 2015). Similarly, in vitro methylation assays using an N-
terminal peptide of the NRMT1 substrate CENP-A, confirmed that NRMT1 has a 
greater affinity for di- versus monomethylated and mono- versus unmethylated 
	 25	
substrates, further explaining the observed processivity of the enzyme (Wu, 
2015).  
Crystal structures of NRMT1 along with SAH (a reaction product and 
methyltransferase inhibitor) and a variety of X-P-K substrates (with X varying 
among six residues) revealed a unique β -hairpin insert between β -strand 5 and 
α-helix 7 and an N-terminal extension consisting of two α -helices are both 
involved in substrate binding and likely to contribute to the substrate specificity of 
the enzyme (Wu et al., 2015; Dong et al., 2015).  Substrate binding is found deep 
within a negatively charged channel connecting to the cofactor binding pocket, 
though the free and peptide-bound structures show little conformational change, 
indicating the likelihood that this pocket it preformed (Wu et al., 2015).  An 
inserted peptide is oriented in such a way to point the α -N-terminal toward the 
cofactor, likely facilitating the methyl transfer. This stereochemistry is unique to 
this enzyme compared to other protein methyltransferases and likely contributes 
to the specificity of N-terminal methylation (Dong et al., 2015).  
Sequence analysis of NRMT1 has yielded one predicted homolog, 
METTL11B (later renamed NRMT2). Primary structure identity between NRMT1 
and NRMT2 is approximately 50%, with key catalytic residues sharing 100% 
sequence identity and spatial location within the catalytic site (Tooley et al., 2010; 
Petkowski et al., 2013). Crystallization of NRMT2 to 2 Å has recently been 
deposited in the protein data bank (PDB: 5UBB), but NRMT2 also has an 
additional 60 amino acid N-terminal domain has yet to be crystalized (Petkowski, 
2013).  NRMT1 and NRMT2 similarly localize to the nucleus, though NRMT1 is 
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ubiquitously expressed, and NRMT2 expression is highly tissue-specific 
(Petkowski, 2013).  NRMT2 is found predominately in the liver and skeletal 
muscle (Petkowski, 2013). 
While sequentially and structurally similar and capable of methylating the 
same consensus sequences, NRMT1 and NRMT2 differ in their catalytic 
specificities (Petkowski, 2013). In vitro methylation assays with recombinant 
NRMT1 or NRMT2, reveal NRMT2 to be exclusively capable of monomethylation 
(Petkowski, 2013).  This is in striking contrast to the mono-, di-, or trimethylase 
activity found in its homologous counterpart (Petkowski, 2013).  Interestingly, the 
rate at which substrates achieved trimethylation was increased when NRMT1 
and NRMT2 were combined, indicating NRMT2 may be serving a priming 
function for NRMT1 by adding the initial methyl group and reducing the substrate 
burden on NRMT1 (Petkowski et al., 2013). This model is further supported by 
the fact that NRMT1 is a distributive methyltransferase with increasing affinity for 
substrates with higher levels of methylation (Wu et al., 2015). Increasing the 
amount of monomethylated substrates available could increase the affinity for 
subsequent di- and trimethylation by NRMT1, which would be useful in times of 
high substrate concentration (Petkowski, 2013).   
 
Functions of N-terminal methylation 
The very first proposed functional role for N-terminal methylation was 
increasing protein stability, as dimethylation of the N-terminal proline of Crithidia 
cytochrome c-557 protected it from tryptic digestion (Smith and Pettigrew, 1980).  
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However, to date, this is the only known substrate where N-terminal methylation 
has been proven to increase protein stability.  More recently, it has been shown 
that N-terminal methylation also promotes protein-DNA interactions (Chen, 
2007).  The binding of RCC1 to chromatin is absolutely necessary for proper 
mitosis, nuclear-cytoplasmic transport, and nuclear envelope assembly 
(Nemurgut et al., 2001; Hetzer et al., 2002).  NRMT1 uniquely methlyates the α-
amino group of RCC1, and mutants of RCC1 that can’t be methylated (lysine 4 of 
the consensus sequence is mutated to a glutamine - K4Q) fail to localize to 
chromatin during mitosis (Chen et al., 2007).  In vitro binding assays have shown 
that N-terminal methylation of RCC1 directly promotes its interaction with DNA 
and not the histone proteins (Chen, 2007).  It is hypothesized that the permanent 
positive charge on the α -N terminus of RCC1, resulting from N-terminal 
trimethylation, facilitates electrostatic binding to the phosphate backbone of DNA 
(Stock et al, 1987; Chen et al., 2007).  The diffuse distribution and decreased 
association with DNA of the K4Q-RCC1 mutants results in an increased 
frequency of multipolar spindles and an eventual disruption of mitosis, providing 
one example of the biological importance of N-terminal methylation (Chen et al., 
2007).  
Another proven target for N-terminal methylation is damaged DNA binding 
protein-2 (DDB2) (Cai et al., 2014).  DDB2 exhibits high affinity for UV light-
induced cyclobutane pyrimidine dimers (CPD) and other bulky DNA adducts 
produced by a number of carcinogens (de Laat et al., 1999). UV-DDB (a 
heterodimer complex of DDB1 and DDB2) functions as a global genome 
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nucleotide excision repair (NER) factor, where DDB2 acts to detect UV-damaged 
chromatin and recruit xeroderma pigmentosum complementation group C (XPC) 
(Moser et al., 2005). DDB2 features an N-terminal Ala-Pro-Lys (A-P-K) 
consensus sequence, and is mono-, di-, and trimethylated on the N-terminal 
alanine residue by NRMT1 (Cai et al., 2014). NRMT1-induced N-terminal 
methylation promotes nuclear localization of DDB2, facilitated recruitment of 
DDB2 to CPD foci, increased CPD repair efficiency, induced proper cell-fate 
decisions via ATM activation, and increased resistance of cells to UV damage 
(Cai et al., 2014). Methylation-defective mutants of DDB2 are defective in nuclear 
localization and recruitment to CPD foci (Cai et al., 2014). This is predicted to be 
through a mechanism similar to RCC1, whereby N-terminal methylation 
enhances the binding of DDB2 to DNA though electrostatic interaction (Cai et al., 
2014).  
NRMT1 has also been implicated in double-stranded break repair (DSB), 
and as such, to function as a tumor suppressor (Bonsignore (1) et al., 2015).  
Loss of NRMT1 results in increased sensitivity of human breast cancer cell lines 
to both etoposide and ɣ-irradiation, agents that cause double strand DNA breaks 
(Bonsignore (1) et al., 2015).   Loss of NRMT1 also increases the proliferation 
rate, invasive potential, anchorage-independent growth, xenograft tumor size, 
and sensitivity to tamoxifen of these breast cancer cell lines (Bonsignore (1) et 
al., 2015). The exact mechanism of how NRMT1 depletion sensitizes cancer 
cells to double stand breaks remains to be determined, but both BRCA-
associated protein-1 (BAP1) and poly [ADP-ribose] polymerase-3 (PARP3) are 
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predicted NRMT1 targets involved in homologous recombination and non-
homologous end-joining, respectively.  As with DDB2, N-terminal methylation 
may also regulate their recruitment to damaged-DNA (Bonsignore (1) et al., 
2015).  
In accordance with the phenotypes seen with NRMT1 knockdown in cell 
culture, global knockout of NRMT1 in mice (NRMT1-/- mice) gives rise to 
phenotypes similar to that seen in other mouse models defective in DNA damage 
repair (Bonsignore (2) et al., 2015; de Boer, et al., 2002). NRMT1-/- mice typically 
die before three weeks of age, are smaller than their wildtype counterparts, 
exhibit female-specific sterility, have marked kyphosis, decreased mitochondrial 
function, and increased liver pathogenesis (Bonsignore (2) et al., 2015). NRMT1-
/- livers show altered expression of genes related to apoptosis, oxidative 
phosphorylation, fatty acid metabolism, and steroid biosynthesis (Bonsignore (2) 
et al., 2015). Given the number of NRMT targets, it is likely these mice aren’t 
merely deficient in DNA damage repair (as demonstrated by Chen et al., 2007 
and Bonsignore (1) et al., 2010), but are likely deficient in a number of protein-
protein and protein-DNA interactions as well.   
As NRMT1 has now been shown to have significant biological relevance, 
we are interested in determining more about its regulation.  We have previously 
seen that co-expression with NRMT2 activates NRMT1 trimethylase activity and 
are especially interested in how this is occurring.  Recent studies with other 
homologous methyltransferases have identified a new pattern of regulation 
through heterodimer formation (Liu et al., 2014; Wang et al., 2016).  The major 
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type I arginine methyltransferase in Trypanosoma brucei, PRMT1, is activated 
through binding of its inactive homologous prozyme, PRMT3 (Kafkova, 2017).  
Though PRMT3 has no activity itself, through binding, it stabilizes and activates 
PRMT1 (Kafkova, 2017).   
Similarly, the N6-methyadenosine (m6A) RNA methyltransferase METTL14 
was recently reported to form a heterodimer complex with its homolog METTL3. 
Both METTL14 and METTL3 have methyltransferase activity individually, though 
the METTL14-METTL3 complex shows dramatically enhanced methyltransferase 
activity compared to either enzyme alone (Liu et al., 2014). Both enzymes 
contain catalytic domains, though phylogenetic analysis shows a much more 
conserved DPPW domain in METTL3 compared to the variable motif of 
METTL14 (Bujnicki et al., 2002; Iyer et al., 2016). The crystal structure of the 
METTL3-METTL14 complex, along with its bound cofactor SAM, has been 
solved to 1.70 Å and 1.65 Å, respectively. There are steric clashes in the 
METTL14 when SAM is bound that aren’t present in METTL3, indicating that 
METTL3 is the catalytic subunit of the complex. However, as METTL3 has 
minimal activity alone, its interaction with METTL14 is structurally necessary to 
lead to catalytic action (Wang et al., 2016). A similar mechanism of synergistic 
complex formation is found in DNA methylation, with the binding of catalytically 
inactive DNMT3L with active DNMT3a or DNMT3b (Jia, et al., 2007). The 
following chapter will explore the hypothesis that NRMT1 and NRMT2 also 
complex in a heterodimer, with the less active NRMT2 stabilizing and activating 






Figure 1. Model of predicted NRMT1 and NRMT2 heterodimer complex, with the 




THE N-TERMINAL METHYLTRANSFERASE HOMOLOGS NRMT1 AND 




The initial defining feature of methyltransferase enzymes was onto which type of 
substrate they catalyzed the transfer of methyl groups from S-adenosyl-
methionine (SAM).  DNA methyltransferases have been further characterized into 
those that place 5’methylcytosine de novo or maintain it at hemimethylated CpG 
sites (Holliday and Pugh 1975).  Protein methyltransferases have been further 
characterized by the amino acid they methylate and the level (mono, di, or tri) of 
methylation they catalyze (Boriack-Sjodin and Swinger 2016).  Likewise, the RNA 
methyltransferases have been divided into four superfamilies based on their 
structure and the nucleotide they methylate (Motorin and Helm 2011).  It is 
becoming clear, however, that in addition to these intrinsic methyltransferase 
qualities, there is an additional layer of functional regulation in their expression 
patterns and complex formation. 
A common theme emerging is complex formation between 
methyltransferase homologs.  In Trypanosoma brucei, the major type I arginine 
methyltransferase, PRMT1, has a very narrow substrate specificity and weak 
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activity in vitro (Kafkova et al. 2017).  However, co-expression with its close 
paralog PRMT3 increases PRMT1 stability, and subsequently, its activity 
(Kafkova et al. 2017).  PRMT3 is missing key catalytic residues and does not 
exhibit in vitro enzymatic activity and has been characterized as a prozyme 
(Kafkova et al. 2017).  Activation of a catalytically weak enzyme by an inactive 
prozyme paralog has also been seen in T. brucei polyamine biosynthesis and 
described as the prozyme paradigm (Willert, Fitzpatrick, and Phillips 2007).  On 
average, the enzyme/prozyme complex typically exceeds the activity of the active 
enzyme alone by 2000 fold (Willert, Fitzpatrick, and Phillips 2007; Nguyen et al. 
2013).   
Similarly, the recently discovered N6-methyladenosine (m6A) RNA 
methyltransferase METTL3 forms a heterodimer with its close homolog 
METTL14 (Liu et al. 2014).  Unlike T. Brucei PRMT1 and PRMT3, METTL3 and 
METTL14 each show weak methyltransferase activity in vitro (Liu et al. 2014; 
Wang et al. 2016).  However, m6A methylation activity is significantly increased 
upon heterodimer formation, and this binding also promotes reciprocal stability of 
the homologs (Liu et al. 2014; Wang et al. 2014).  Though these data suggest 
METTL14 is not strictly an inactive prozyme, it appears its catalytic activity is not 
required for in vivo activity of the complex (Wang, Doxtader, and Nam 2016).  
The crystal structure of the heterodimer catalytic domains also indicates the 
METTL14 catalytic site is relatively occluded and does not bind SAM (Wang, 
Doxtader, and Nam 2016).  The current model is that the primary role of 
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METTL14 is to provide structural support to METTL3 and interact with RNA 
substrate (Wang, Doxtader, and Nam 2016; Wang et al. 2016). 
The mammalian methyltransferase EZH2 is part of the PRC2 complex that 
represses transcription by di- and trimethylating histone H3 on lysine 27 
(H3K27me2/3) (Schuettengruber et al. 2007).  EZH2 has one close homolog, 
EZH1, which also interacts with members of the PRC2 complex (Margueron et al. 
2008).  PRC2-EZH1 can also repress transcription, but EZH1 has weak 
H3K27me2/3 activity (Margueron et al. 2008).  In contrast to PRC2-EZH2, PRC2-
EZH1 represses transcription by binding and compacting nucleosomes 
(Margueron et al. 2008).  The PRC2-EZH2 and PRC2-EZH1 complexes are 
thought to be primarily mutually exclusive, but data indicate EZH1 and EZH2 can 
interact with each other both in vitro and in vivo (Margueron et al. 2008; Oliviero 
et al. 2016).  It is still functionally unclear why a PRC2 complex that contains 
EZH2 would also contain EZH1 (Oliviero et al. 2016), but as they accomplish the 
same goal by different mechanisms, there may be certain circumstances when 
synergistic activity would be beneficial.  Unlike T. brucei PRMT1 and PRMT3 and 
mammalian METTL14 and METTL3, Ezh1 and Ezh2 have very different 
expression patterns (Margueron et al. 2008), and the need for complexed EZH1 
and EZH2 may be specific to the tissues and developmental times where their 
expression patterns overlap. 
We work on the N-terminal methyltransferase homologs NRMT1 (N-
terminal RCC1 methyltransferase 1) and NRMT2 (N-terminal RCC1 
methyltransferase 2), which, following cleavage of the initiating methionine, 
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methylate the α-amine of the first N-terminal residue of their substrates.  NRMT1 
and NRMT2 are 50% identical and 75% similar and share an N-terminal X-P-K 
consensus sequence (Petkowski et al. 2013; Petkowski et al. 2012).  Though 
structurally similar, they differ in their catalytic activities. In vitro, NRMT1 exhibits 
distributive trimethylase activity, and in vivo, complete knockout of NRMT1 via 
homologous recombination or CRISPR/Cas9 abolishes N-terminal trimethylation 
(Petkowski et al. 2013; Shields et al. 2017; Bonsignore, Tooley, et al. 2015).  
NRMT2 exhibits monomethylase activity in vitro (Petkowski et al. 2013), but its 
knockout phenotypes remain to be characterized due to lack of an antibody that 
successfully detects it endogenously.  
There are over 300 predicted NRMT targets (Petkowski et al. 2012) and 
over a dozen verified targets, including RCC1, the tumor suppressor 
Retinoblastoma protein (Rb), the histone chaperone SET, the centromere 
proteins CENP-A and CENP-B, Poly(ADP-Ribose) Polymerase 3 (PARP3), 
Damaged DNA-binding protein 2 (DDB2), and a variety of myosin light chains 
and ribosomal proteins (Bailey et al. 2013; Dai et al. 2013; Dai et al. 2015; Cai et 
al. 2014; Tooley et al. 2010).  For the verified targets, N-terminal methylation 
seems to predominantly regulate protein-DNA interactions.  Loss of N-terminal 
methylation of RCC1 disrupts its binding to DNA, its localization to chromatin, 
and its ability to properly establish mitotic spindles (Chen et al. 2007).  N-terminal 
trimethylation of CENP-B enhances its binding to α-satellite DNA (Dai et al. 
2013), and N-terminal trimethylation of CENP-A is also required for its 
recruitment to the centromere (Sathyan, Fachinetti, and Foltz 2017).  DDB2 that 
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cannot get N-terminally methylated cannot be as efficiently recruited to UV-
induced cyclobutane dimers and these dimers cannot be as effectively repaired 
(Cai et al. 2014). 
  NRMT1 and NRMT2 have distinct mRNA expression patterns. NRMT1 is 
expressed ubiquitously in all tissues, while NRMT2 has much lower, tissue-
specific expression, with its highest expression found in the skeletal muscle and 
the liver (Petkowski et al. 2013).  This indicates NRMT1 can function 
independently without NRMT2.   In addition, NRMT1 knockout does not 
significantly affect monomethylation levels (Shields et al. 2017), indicating that 
even at low levels, NRMT2 can function without NRMT1 present. Taken together 
these data indicate both NRMT1 and NRMT2 can function independently without 
the other present.  However, it is unknown if N-terminal mono- and trimethylation 
are functionally redundant, and in vitro co-expression of NRMT2 with NRMT1 is 
able to increase the trimethylation activity of NRMT1 (Petkowski et al. 2013), 
indicating the two may also work synergistically under certain conditions.  
Here I aimed to better understand the interdependence of NRMT1 and 
NRMT2 and determine if they function in a complex.  First, I used analytical 
ultracentrifugation to show that purified recombinant NRMT1 and NRMT2 interact 
and determined the stoichiometry of interaction as 2:1 NRMT1 to NRMT2.  Next, 
I used co-immunoprecipitation (co-IP) to show NRMT1 and NRMT2 can be found 
complexed together in vivo and molecular modeling to map their areas of 
interaction.  I also used cycloheximide experiments to determine that while the 
half-life of NRMT1 increases in the presence of overexpressed NRMT2, the 
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converse is not true.  I used kinetic assays to quantitatively determine the effect 
of NRMT2 expression on NRMT1 activity and site directed mutagenesis to 
determine that NRMT2 enzymatic activity is not needed for an increase in 
NRMT1 trimethylase activity or substrate affinity.  Finally, to determine if N-
terminal mono- and trimethylation are functionally redundant, I tagged the NRMT 
substrate SETα with Dendra2 photoswitchable protein and showed its half-life is 
significantly decreased in NRMT1 CRISPR/Cas9 knockout cells.  This decrease 
in half-life can be rescued by NRMT1 overexpression but not by overexpression 
of NRMT2.  From these data, I conclude that NRMT1 and NRMT2 are most 
similar to their family members METTL3 and METTL14, which both exhibit 
methyltransferase activity in vitro but the activity of METTL3 predominates in 
vivo.  Stability and substrate affinity are increased by complex formation and 
monomethylase priming activity is not required.  These data do not rule out an 
additional unique function of N-terminal monomethylation by NRMT2, but show 
one of its functions when expressed is to promote N-terminal trimethylation. 
 
Materials and methods 
Constructs and antibodies 
For recombinant protein production, full-length human NRMT1, NRMT2, and 
NRMT2 V224L were cloned into pet15b (Merck Millipore, Burlington, MA) and 
purified as described previously (Petkowski et al. 2013; Chen, Brownawell, and 
Macara 2004; Shields et al. 2017). The full-length human NRMT1-FLAG, 
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NRMT1-GFP, NRMT2-FLAG, and NRMT2-GFP used in the co-IPs were cloned 
into pKH3 (FLAG constructs) or pKGFP2 (GFP constructs), as previously 
described (Petkowski et al. 2013).  All truncated constructs were sub-cloned from 
these full-length ORFs using primer sets that combined the primers used for full-
length cloning and the following unique primers:  
NRMT11-59 Reverse: 5’-GGGAATTCTTGTTCGGGCCTTCCCTCA-3’, 
NRMT152-172 Forward: 5’-GGTCTAGAATGTTTTTGAGGGAAGGCCCGAAC-3’ 
NRMT152-172 Reverse: 5’-GGGAATTCTCCTGGGCCATGTTGTCTTTGATGAC-3’ 
NRMT1178-223 Forward: 5’-GGTCTAGAATGGACGTGGACAGCAGCGTGTGC-3 
NRMT21-112 Reverse: 5’-GGGGATCCCCAGGCCCCCCAACAAATTT-3’ 
NRMT277-223 Forward: 5’-GGTCTAGAATGCAAGAAGTACCAGCCACAGAA-3’ 
NRMT277-223 Reverse: 5’- GGGGATCCGTCCTTCAATATGATGATGCC-3’ 
To make SETα-Dendra2-pCDH, human SETα was amplified from our previously 
published SETα-FLAG construct (Tooley et al. 2010) to introduce 5’ Xho1 and 3’ 
HindIII restriction sites and sub-cloned into the pDendra2-N vector (Clontech, 
Mountain View, CA). The SETα-Dendra2 construct was then amplified to 
introduce 5’ Xba1 and 3’ Swa1 restriction sites and sub-cloned into the lentiviral 
vector pCDH-CMV-EF1-Puro (pCDH, Addgene, Cambridge, MA).  Lentivirally 
expressed NRMT2-GFP, NRMT1-FLAG, and NRMT2-FLAG were first amplified 
from the corresponding mammalian expression vectors to introduce 5’ Xba1 and 
3’ Swa1 restriction sites and sub-cloned into pCDH.  Primary antibodies for 
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western blots were used at the following dilutions: rabbit anti-FLAG-HRP (1:1000, 
Sigma-Aldrich, St. Louis, MO), rabbit anti-GFP (1:1000, Cell Signaling 
Technologies, Danvers, MA), rabbit anti-NRMT1 (1:1000) (Tooley et al. 2010), 
rabbit anti-me3-RCC1 (1:10,000) (Tooley et al. 2010), rabbit anti-me1/2-RCC1 
(1:5000) (Tooley et al. 2010), rabbit anti-GAPDH (1:2000, Trevigen, 
Gaithersburg, MD), and mouse anti-Dendra2 (1:500, Origene, Rockville, MD). 
 
Cell culture and lentivirus production 
Human embryonic kidney cells (HEK293, ATCC, Manassas, VA) cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Atlanta 
Biologicals) and 1% penicillin-streptomycin (P/S; Life Technologies). HCT116 
human colorectal carcinoma cell lines (generous gift from Dr. Ian Macara) were 
maintained in McCoy’s 5a Modified Medium (Life Technologies) supplemented 
with 10% FBS and 1% P/S.  Lentivirus expressing empty pCDH vector, NRMT2-
GFP-pCDH, SETα-Dendra2-pCDH, NRMT1-FLAG-pCDH, or NRMT2-FLAG 
pCDH was made by co-transfecting HEK293 cells with 50 µg pCDH containing 
the appropriate cDNA, 37.5 µg psPAX2 packaging vector, and 15 µg pMD2.G 
viral envelope plasmid using calcium phosphate transfection (McCaffrey and 
Macara 2009). Forty-eight hours post-transfection, supernatant was collected 
and virus concentrated using 100 kD ultrafilters (EMD Millipore). Virus 
concentration was determined by titration in HEK293 cells and HCT116 cells 
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were transduced by addition of a volume of virus equal to a multiplicity of 
infection (MOI) of 1. Three days post-transduction, transduced cells were 
selected for by addition of 2 µg/ml puromycin. For Dendra2 experiments, cells 
were first transduced with overexpression virus.  Transduced cells were selected 




For co-IP experiments, 1x106 HEK293 cells were seeded in 60 mm tissue culture 
dishes 24 hours prior to calcium phosphate transfection with 2 µg each of 
appropriate constructs.  24 hours post-transfection, cells were scraped directly 
into 100 µl lysis buffer (50mM Tris pH 7.5, 300 mM NaCl, 5 mM MgCl2, 1% NP-
40, 7mM BME) plus protease inhibitors for protein isolation.  20 µl of cell lysate 
was retained for input control, and the remainder mixed with 20 µl M2 agarose 
beads (Sigma-Aldrich). The bead/protein mixture was rotated 1-2 hours at 4oC 
and washed 3x with PBS + 0.1% NP-40. The immunoprecipitated proteins were 
eluted from the beads in 5X Laemmli buffer and boiled for 5 minutes at 95o C. 
The bead-free supernatant from IP and 15ug total protein input samples were run 





Sedimentation velocity experiments were carried out in a Beckman Coulter 
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter Inc., Brea, CA) at 
20°C and 40,000 rpm in standard 2 sector cells. Buffer density and viscosity (50 
mM Tris, 50 mM KCl at pH 8.0) were calculated using Sednterp (free software: 
Biomolecular Interaction Technologies Center at the University of New 
Hampshire, http://jphilo.com/sdtr0601.exe). Data were analyzed with the program 
Ultrascan 3.0 (free software: www.ultrascan.uthscsa.edu/) using the “combine 
pseudo-3D distributions” operation. The partial specific volumes of NRMT1 and 
NRMT2 were calculated from the amino acid compositions (0.734 ml/g for 
NRMT1 and 0.737 ml/g for NRMT2) using the Protparam tool in ExPASy (free 
software: web.expasy.org). Dr. Bill Dean is greatly appreciated for performing the 
analytical ultracentrifugation and subsequent analysis.  
 
Cycloheximide experiments 
1x106 HCT116 cells, HCT116 cells transduced with lentivirus expressing NRMT2-
GFP, HCT116 cells with CRISPR/Cas9-mediated knockout of NRMT1 (HCT116 
NRMT1-/-) (Shields et al. 2017), or HCT116 NRMT1-/- cells transduced with 
lentivirus expressing NRMT2-GFP were plated 24 hours prior to the start of the 
cycloheximide chase experiment. At the start of each time point, the McCoy’s 5a 
Modified Medium was replaced with fresh media containing 100 µg/ml 
cycloheximide (Sigma-Aldrich). Cells were harvested in 100 µl cell lysis buffer 
(see above) and protein was quantified using the Pierce 660 nM Protein Assay 
(Thermo-Fisher Scientific, Waltham, MA). 20 µg total protein per time point was 
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separated on 12% SDS-PAGE gels and subjected to Western blotting using 
antibodies against NRMT1, GFP, and GAPDH as a loading control. Pixel density 
and normalization for each band was quantified using Image Lab software (Bio-
Rad, Hercules, CA). 
 
Dendra2 experiments 
As described above, HCT116 or HCT116 NRMT1-/-  cells were transduced with 
control (empty pCDH vector), NRMT1-FLAG, or NRMT2-FLAG expressing 
lentivirus at an MOI of 1.  Three days post-transduction cells were selected with 
puromycin treatment. Three days post-puromycin treatment, cells were 
retransduced with lentivirus expressing SETα-Dendra2 at an MOI of 1. 72 hours 
post-transduction, 2000 cells per well of each experimental condition were plated 
at an N=6 on a 96-well plate and allowed to adhere and grow for 48-72 hours.  
Kinetic fluorescent analysis using the Cytation5 Imaging System (BioTek, 
Winooski, VT) was started by taking pre-conversion images in the GFP and RFP 
channel for each well. Each well was then exposed to the DAPI channel (UV) at 
maximum intensity for 16 seconds for photoconversion of the Dendra2. Post-
conversion RFP kinetic imaging was performed once per hour for 24 hours, with 
cells maintained at 5% CO2 and 37°C.  Imaging settings remained constant 
throughout.  The raw fluorescence value of the RFP channel for each well was 
then normalized to the 0-hour time point and fluorescent decay between cell 
types was measured.  
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In vitro methylation assays 
Methyltransferase assays were conducted using the MTase-Glo 
Methyltransferase Assay (Promega, Madison, WI) and following the given 
protocol. Briefly, after optimization for protein concentration, all assays used 0.4 
µM recombinant enzyme, 20 µM S-adenosyl methionine (SAM), and varied 
concentrations of SPK-RCC1 (SPKRIAKRRSPPADA) or SSK-MYL9 
(SSKRAKAKTTKKRPK) peptides as substrate. Substrates were serially diluted in 
a 96-well plate and reactions were started with the addition of the appropriate 
recombinant enzyme.  All reactions were carried out at room temperature and 
stopped after 20 minutes with the addition of 0.5% trifluoroacetic acid. The 
MTase-Glo detection reagents were then added and luminescence was 
quantified using the Cytation5 Imaging System (BioTek).  
 
Protein modeling and statistical analysis 
Molecular modeling and the associated images were produced using the PyMOL 
Molecular Graphics System, Version 2.0.6 (Schrödinger, LLC).  PDB accession 
numbers are 2EX4 (NRMT1) and 5UBB (NRMT2).  Modeling was performed by 
molecular alignment of monomeric species of NRMT2 (5UBB) and dimeric 
NRMT1 (2EX4). Each species was rotated to minimal root-mean-square 
deviation (RMSD) scores (adapted from Coutsias et al., 2004) and potential 
interacting residues were measured using the “measurement wizard,” natively 
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incorporated into the PyMOL user interface. All measured residues of interaction 
had a distance >4Å, satisfying the maximum Van der Waals radius between 
atoms involved. All statistical analyses were performed using GraphPad Prism 
Software for Mac Version 7.0d (La Jolla, California). The specific statistical test is 
noted in the respective figure captions and results are presented as mean ± 
standard error, n = 3 unless specifically stated. 
 
Results 
NRMT1 and NRMT2 form heterotrimers 
Like METTL3 and METTL14, NRMT1 (METTL11A) and NRMT2 (METTL11B) are 
part of the Methyltransferase like (METTL) family of class I methyltransferases 
containing seven-beta-strand methyltransferase motifs and Rossman folds for 
binding SAM (Iyer, Zhang, and Aravind 2016; Schapira and Ferreira de Freitas 
2014).  Though the enzymes in the METTL family have a wide range of 
substrates, including protein, RNA, and small molecules, they are structurally 
similar (Richon et al. 2011).  Given that METTL3 and METTL14 must form a 
heterodimer for optimal m6A methylation activity (Liu et al. 2014), and NRMT1 
has been shown to have increased N-terminal trimethylation activity when co-
expressed with NRMT2 (Petkowski et al. 2013), I wanted to determine if NRMT1 
and NRMT2 also heterodimerize. 
 His-tagged recombinant human NRMT1 and NRMT2 were expressed and 
purified from E. coli and analyzed individually and combined by analytical 
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ultracentrifugation.  Ultrascan 3 analysis identified a pool of NRMT1, that when 
analyzed alone, sediments as a monomer of approximately 33 kD (Figure 2A).  
This is slightly larger than the predicted molecular mass of 25 kD for a NRMT1 
monomer.  The majority of NRMT1, however, sedimented as a 52 kD dimer 
(Figure 2A).  NRMT2 showed an opposite pattern when run alone.  There was a 
pool of NRMT2 that sedimented as a 52.6 kD dimer, but the majority sedimented 
as a 35.7 kD monomer, which is close to its predicted molecular mass of 32 kD 
(Figure 2B).  When run in combination at equimolar concentrations, monomers of 
each NRMT1 and NRMT2 were still present, but a new species of 83.8 kD was 
now visible, representing a heterotrimer formed from a NRMT1 dimer and a 
NRMT2 monomer (Figure 2C).  The pool of NRMT1 dimer was completely 
depleted, suggesting that if NRMT2 monomer is present the NRMT1 dimer will 
bind it.  In addition, as there was excess monomeric NRMT1 and NRMT2 present 
and no indication of a NRMT1 and NRMT2 heterodimer, these data also suggest 
NRMT1 cannot bind NRMT2 unless it is already homodimerized and a pool of 










Figure 2. NRMT1 and NRMT2 form heterotrimers. (A) Ultrascan 3 analysis 
shows a minor pool of His-tagged NRMT1 sediments as a monomer of 
approximately 33 kD and a major pool sediments as a homodimer of 
approximately 52 kD. (B) The majority of His-tagged NRMT2 sediments as a 
monomer of approximately 35.7 kD, with a minor pool sedimenting as a 
homodimer of approximately 52.7 kD. (C) An equimolar mixture of NRMT1 and 
NRMT2 shows the formation of an 83.8 kD heterotrimeric species, representing a 
NRMT1 dimer and NRMT2 monomer. NRMT1 dimers are no longer present, but 
monomers of both NRMT1 and NRMT2 can still be seen. Dr. Bill Dean is greatly 
thanked for the running and interpretation of the analytical ultracentrifugation 
experiment.  
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NRMT1 and NRMT2 interact in vivo 
  
Now knowing that NRMT1 and NRMT2 can interact in vitro, I wanted to next 
determine if the homologs also interact in vivo.  Full length C-terminally-tagged 
human NRMT1-FLAG and NRMT2-GFP were co-expressed in human embryonic 
kidney cells (HEK293) by transient transfection.  Twenty-four hours post-
transfection, NRMT1-FLAG was immunoprecipitated (IP) out of the cell lysate 
and western blots were used to determine if NRMT2-GFP co-
immunoprecipitated.  As expected, full length NRMT1-FLAG was able to co-IP 
NRMT2-GFP (Figure 3A).  To test if the reciprocal was true, full length human 
NRMT2-FLAG and human NRMT1-GFP were also co-expressed in HEK293 cells 
by transient transfection.  While NRMT1-GFP did show some non-specific 
binding to beads alone, it was enriched in the co-IP lane, indicating full length 
NRMT2-FLAG is able to co-IP NRMT1-GFP (Figure 3B).   
As both these co-IPs were done with overexpressed tagged proteins, I 
next wanted to determine if endogenous NRMT1 and NRMT2 interact.  We have 
previously developed a rabbit antibody against human NRMT1 that successfully 
works for western blot but not for IP (Tooley et al. 2010).  Though NRMT1 and 
NRMT2 are 50% identical, the fourteen amino acid peptide antigen used to 
produce the NRMT1 antibody only had three amino acids in common and does 
not appear to detect NRMT2 (Tooley et al. 2010).  As we have yet to find a 
NRMT2 antibody that consistently works for either western blot or IP from cell 
lysate, I expressed full length NRMT2-FLAG in HEK cells, immunoprecipitated it 
with anti-FLAG agarose and assayed for the presence of endogenous NRMT1 by 
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western blot.  As a control, I also expressed VRK2-FLAG, which has been shown 
to interact with endogenous NRMT1 (Petkowski et al. 2012).  I found that 
endogenous NRMT1 did co-IP with both VRK2-FLAG and NRMT2-FLAG (Figure 
3C).  Taken together, these data indicate that NRMT1 and NRMT2 can interact 







Figure 3.  NRMT1 and NRMT 2 interact in vivo (A) Western blots showing 
NRMT2-GFP co-immunoprecipitates with NRMT1-FLAG after co-transfection into 
HEK293 cells. (B) Reciprocally, NRMT1-GFP co-immunoprecipitates with 
NRMT2-FLAG. (C) Endogenous NRMT1 co-immunoprecipitates with both 
NRMT2-FLAG and VRK2-FLAG (a known binding partner of NRMT1, used as a 
positive control) (Petkowski et al. 2012). * denotes NRMT1 band. Upper band is 




Modeling of NRMT1 and NRMT2 interactions  
 
I next wanted to determine which domains on NRMT1 and NRMT2 are 
responsible for heterotrimer formation.  The crystal structures of NRMT1 and 
NRMT2 (PDB codes 2EX4 and 5UBB) have been determined to 1.75 and 2 Å, 
respectively (Min 2005; Dong 2017), and as predicted by homology modeling 
(Petkowski et al. 2013) are almost identical barring the additional N-terminal 
domain on NRMT2, which was not included in the structure (Dong 2017). The 
core of both enzymes is a seven-stranded β sheet (β1-7) flanked by five α -
helices (α1-5) (Wu et al. 2015).  In addition, there are several other structural 
elements including three N-terminal helices and a pair of β hairpins (βAB) inserted 
between β5 and α6 (Wu et al. 2015).   
To help predict which domains of NRMT1 and NRMT2 interact, I first used 
PyMOL molecular visualization software to model the NRMT1 dimer.  The space-
filling model (Figure 4A) and ribbon diagram (Figure 4B) indicate NRMT1 
homodimerization is facilitated by α5 of one monomer and the loop between 
α1/β1 on the second monomer (Figure 4B). Neither of these regions are involved 
in either the substrate or SAM-binding motifs (Wu et al. 2015) but are exposed on 
the outside of the protein and would be available for interaction (Figure 4A).  The 
model specifically predicts interactions between Ser157 and Gly156 of the α5 
helix with Ser64 and Arg68 of the α1/β1 loop, which are 4.2 and 3.9 Å apart, 
respectively (Figure 4C). 
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Though our analytical ultracentrifugation results suggest NRMT2 is 
predominantly found as a monomer, it can also be found as a homodimer (Figure 
2B), and these dimerization interactions could provide insights into how it 
heterotrimerizes with NRMT1.  The NRMT2 crystal structure (PDB code 5UBB) 
and our PyMOL models of NRMT2 dimerization (Figure 4D, E), indicate its 
homodimerization is facilitated by the unstructured N-termini (minus the 59 amino 
acid region unique to NRMT2, which is not included in the crystal structure) and 
the βAB hairpins of each monomer.  Our model specifically predicts Gln60, Val61, 
and Ile62 of the N-terminus interact with Cys229, Ile230, and Leu231 of the βAB 
hairpin, respectively (Figure 4F).  The extreme N-terminus is not currently 
predicted to contribute to substrate or SAM binding (Wu, 2015), but it is hard to 
predict how the additional 59 amino acid NRMT2 N-terminal tail could affect the 
overall structure.  The βAB hairpins are predicted to contribute to the substrate-
binding pocket (Wu et al. 2015), which indicates binding of NRMT2 to NRMT1 







Figure 4.  Modeling of NRMT1 and NRMT2 dimers. Space-filling model of (A) 
NRMT1 and (D) NRMT2 homodimers showing regions of dimerization (green 
overlap, middle).  Ribbon diagrams of (B) NRMT1 and (E) NRMT2 homodimers 
and detail of regions of interaction between monomers. All measurements 
between residues fall within accepted Van der Waals distances for interaction. 
Boxed regions are enlarged below each model.  Measured distances between 
interacting residues from monomers of (C) NRMT1 and (F) NRMT2. All 





 I next used PyMOL to model the possible interactions between a NRMT1 
dimer and a NRMT2 monomer (Figure 5A).  I found that if the previously modeled 
interactions between NRMT1 monomers are maintained, the NRMT2 monomer 
primarily interacts within the first 50 amino acids of NRMT1, with a secondary set 
of interactions between Arg79, Pro83, andTyr104 of NRMT1 and Leu231, 
Asp232, and Gln60 of NRMT2 (Figure 5A-C).  The NRMT2 residues involved are 
almost identical to those involved in homodimerization (Figure 5C).  As predicted, 
the model suggests that NRMT2 interacts with the NRMT1 dimer as it would with 
another NRMT2 monomer.  As the N-terminus of NRMT1 is not needed for its 
dimerization, both NRMT1 monomers would theoretically be available for binding 
to NRMT2.  However, NRMT1 dimerization places both N-termini in the same 
plane, so steric hindrance may preclude binding of more than one NRMT2 






Figure 5.  Modeling of NRMT1 and NRMT2 heterotrimer. (A) Top - Space-filling 
model showing area of interaction between the NRMT1 dimer (green) and 
NRMT2 monomer (multicolored). Bottom - 180
o
 rotation of the heterotrimer 
model. The NRMT2 monomer is shaded with a blue-to-red gradient, representing 
the N-terminal to C-terminal orientation of the amino acid sequence. The majority 
of interactions between the NRMT1 dimer and NRMT2 monomer are predicted to 
involve the blue (N-terminus) shaded region of NRMT2. (B) Ribbon diagram of 
the NRMT1 dimer interacting with the space-filling model of the NRMT2 
monomer. Boxed region is enlarged below and shows the majority of residues of 
interaction are found in the N-terminus of both enzymes. (C) Diagram of and 
measured distances between interacting residues of NRMT1 and NRMT2. (D) 
Ribbon diagram of NRMT1 homodimer, indicating N-termini of each monomer 
(purple) are oriented in the same plane.  All interactions were modeled with 






 To test these models, I performed co-IPs with N- and C-terminal 
fragments of NRMT1 and NRMT2 (Figure 6A).  To determine if it is primarily the 
unstructured N-terminal tail of NRMT2 that interacts with full-length NRMT1-
FLAG, I made constructs consisting of the first 112 amino acids of NRMT2 
(containing important predicted residues) or amino acids 77-223 of NRMT2 
(directly succeeding the important predicted residues) fused to GFP.  An 
additional C-terminal fragment of NRMT2 (amino acids 207-283) was attempted 
but did not express.  NRMT1-FLAG and NRMT21-112-GFP or NRMT277-223-GFP 
were co-expressed in HEK293 cells, and NRMT1-FLAG was immunoprecipitated 
using anti-FLAG antibody conjugated to agarose beads.  Contrary to the model, 
the first 112 amino acids of NRMT2 did not strongly interact with NRMT1, though 
amino acids 77-223 did (Figure 6B,C).  The main difference between the co-IPs 
and the models was that the first 112 amino acids in the co-IPs contained the 
extra 59 amino acid N-terminal tail that was not included in the crystal structure 
or subsequent model.  These data indicate that the presence of the additional N-
terminal amino acids of NRMT2 affect its binding to NRMT1. 
 To determine if it is primarily the first 50 amino acids of NRMT1 that 
interact with full-length NRMT2-FLAG, I made constructs consisting of the first 59 
amino acids, amino acids 52-172, or amino acids 178-223 of NRMT1 fused to 
GFP (Figure 6A).  NRMT2-FLAG and NRMT11-59-GFP, NRMT252-172-GFP, or 
NRMT2178-223-GFP were co-expressed in HEK293 cells, and NRMT2-FLAG was 
immunoprecipitated out as previously described. Supporting the model, the first 
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59 amino acids of NRMT1 did strongly interact with NRMT2 (Figure 6D).  
However, amino acids 52-172 also interacted with NRMT2 (Figure 6E), as did 
amino acids 178-223, though to a lesser degree than the first two constructs 
(Figure 6F).  These data indicate that the first 50 amino acids of NRMT1 are 
sufficient to promote interaction with NRMT2, though the predicted interactions of 








































Figure 6.  NRMT1 and NRMT2 truncation mutants.  (A) Diagram showing full-
length and truncation constructs of NRMT1 and NRMT2.  Subscript indicates the 
amino acid (aa) sequence from N- to C-terminus of each construct. (B) Full-
length NRMT1-FLAG only weakly interacts with the first 112 aa of NRMT2, (C) 
though strongly interacts with a NRMT2-GFP fragment (amino acids 77-223) that 
is missing the 59 aa tail that is also lacking from the crystal structure and 
subsequent model. (D) Full-length NRMT2-FLAG strongly interacts with the first 
59 aa of NRMT1, as well as, (E) amino acids 52-172. (F) There is a decreased 
interaction of NRMT2-FLAG with the C-terminal fragment of NRMT1 (amino 




NRMT2 expression stabilizes NRMT1 
 
As both PRMT1 and METTL3 stability is enhanced by binding to its homolog 
partner (Kafkova et al. 2017; Liu et al. 2014; Wang et al. 2014), I wanted to next 
determine if the half-life of NRMT1 is enhanced by the expression of NRMT2 or 
vice versa.  To first measure the half-life of endogenous NRMT1 under basal 
conditions (i.e. low levels of NRMT2 as determined by qRT-PCR (unpublished 
data)), I treated HCT116 human colorectal carcinoma cells with 100 µg/ml 
cycloheximide and harvested cell lysates at six time points, up to twelve hours 
after treatment.  Western blots of the lysates were probed with our anti-NRMT1 
antibody (Tooley et al. 2010) and anti-GAPDH as a loading control.  NRMT1 
levels were normalized to GAPDH and calculated using Image Lab software.  
The experimentally calculated half-life for endogenous NRMT1 was 
approximately 8.8 hours (Figure 7A).   
Due to the lack of an antibody that specifically detects endogenous 
NRMT2 in cell lysate, I used NRMT2-GFP to determine the half-life of NRMT2 
under basal conditions.  HCT116 cells were transduced with lentivirus expressing 
NRMT2-GFP at an MOI of 1.  48 hours post-transduction, successfully 
transduced cells were selected for by puromycin treatment.  This was to ensure 
all cells in the experiment were expressing a homogenously low level of NRMT2-
GFP.  Again, cells were treated with 100 µg/ml cycloheximide and harvested at 
six time points, up to twelve hours after treatment.  Western blots of the lysates 
were probed with anti-GFP and anti-GAPDH and analyzed as above.  The 
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experimentally calculated half-life for NRMT2 under basal conditions (i.e. with 
NRMT1 present) was approximately 5.3 hours (Figure 7B). 
 To determine if NRMT2 expression is altered in the absence of NRMT1, I 
first transduced CRISPR/Cas9-mediated NRMT1 knockout HCT116 cells 
(Shields et al. 2017) with lentivirus expressing NRMT2-GFP at an MOI of 1.  After 
puromycin selection, cells were treated with 100 µg/ml cycloheximide and 
harvested as previously described. The experimentally calculated half-life for 
NRMT2 in cells lacking NRMT1 expression was approximately 3.3 hours (Figure 
7C). This was not statistically significant from the half-life of NRMT2-GFP in 
control cells (Figure 7E), indicating the stability of NRMT2 is not dependent on 
NRMT1 expression.  This also highlights the short half-life of NRMT2, and 
indicates its expression may be tightly regulated and confined to times of specific 
need. 
 Next, I aimed to measure if NRMT2 overexpression affects the stability of 
endogenous NRMT1.  As previously, HCT116 cells were transduced with 
lentivirus expressing NRMT2-GFP at an MOI of 1.  They were then treated with 
100 µg/ml cycloheximide and harvested as previously.  Interestingly, in the 
presence of overexpressed NRMT2, the half-life of NRMT1 increases to 
approximately 14.8 hours (Figure 7D).  This is a significant increase in NRMT1 
half-life as compared to its half-life of 8.8 hours under basal NRMT2 conditions 
(Figure 7E).  These data fit with a model of NRMT1 providing basal 
housekeeping N-terminal methyltransferase activity, and NRMT2 being induced 
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Figure 7.  NRMT2 expression stabilizes NRMT1. HCT116 cells were treated for 0 
-12 hours with 100 µg/ml cycloheximide to inhibit protein synthesis. (A) Half-life of 
endogenous NRMT1 protein was calculated to be 8.8 hours. (B) Half-life of 
NRMT2-GFP protein was calculated to be 5.3 hours. (C) HCT116 cells with 
CRISPR/Cas9-mediated knockout of NRMT1 (HCT116 NRMT1-/-) were also 
treated for 0 -12 hours with 100 µg/ml cycloheximide. The half-life of NRMT2-
GFP in the absence of NRMT1 was slightly lower at 3.3 hours (D) Finally, 
HCT116 cells overexpressing NRMT2-GFP were treated for 0 -12 hours with 100 
µg/ml cycloheximide. The half-life of endogenous NRMT1 in the presence of 
overexpressed NRMT2 was found to be a significantly longer 14.8 hours. (E) 
Comparison of the half-lives of each group.  Blots are representative images of 
three independent experiments. Pixel densitometry was quantified using Bio-Rad 
Image Lab software, with GAPDH serving as the loading control for each lane. 
NRMT1 and/or GFP bands were internally normalized to T=0 lane and set to 1.  
Half-life was calculated using a one-phase decay non-linear regression and 
constraining Y0 to 1 and the plateau to 0 (dashed lines).  * denotes p<0.05 as 
determined by ANOVA followed by Tukey’s multiple comparison test to compare 






Catalytic activity of NRMT2 is not necessary for increased trimethylation by 
NRMT1  
To determine if NRMT2 enhances NRMT1 activity through a priming activity as 
previously hypothesized (Petkowski et al. 2013), or if it is simply providing 
enhanced stability, I performed in vitro methylation assays with different 
combinations of wild type (WT) NRMT1, WT NRMT2, and NRMT2 V224L, a 
mutant initially identified in human breast cancer that is almost completely devoid 
of methyltransferase activity (Shields et al. 2017).  When using as substrate a 
peptide consisting of the first fifteen amino acids of RCC1 
(SPKRIAKRRSPPADA), NRMT1 recombinant enzyme alone exhibited a Km of 
1.1 µM (Figure 8A), WT NRMT2 recombinant enzyme alone exhibited a Km of 
55.6 µM (Figure 8B), and NRMT2 V224L had no activity (Figure 8C).  In 
combination with WT NRMT2, the Km of NRMT1 decreased to 0.9 µM (Figure 
8D), and in combination with NRMT2 V224L, the Km of NRMT1 decreased to 0.1 
µM (Figure 8E), indicating the increased activity of NRMT1 is not dependent on 
the catalytic activity of NRMT2. 
 However, only the decrease in Km with NRMT2 V224L was statistically 
significant from the Km of NRMT1 alone (Figure 8F).  As the Ser-Pro-Lys 
consensus sequence of the RCC1 peptide is a preferred substrate for NRMT1 
(Petkowski et al. 2012), I wanted to test if I could see a greater decrease in Km 
with NRMT2 addition when using a less preferred substrate.  We have previously 
seen that the Km of NRMT1 is considerably higher when using the Ser-Ser-Lys 
consensus sequence of myosin regulatory light chain 9 (MYL9) (unpublished 
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data), so I repeated the experiments above using a peptide of the first fourteen 
amino acids of MYL9 (SSKRAKAKTTKKRP) as substrate.  NRMT1 recombinant 
enzyme alone exhibited a Km of 15.6 µM (Figure 8G).  Neither WT NRMT2 nor 
NRMT2 V224L had any activity on the MYL9 peptide (Figure 8H,I).  In 
combination with WT NRMT2, the Km of NRMT1 decreased to 6.6 µM (Figure 
8J), and in combination with NRMT2 V224L, the Km of NRMT1 decreased to 4.4 
µM (Figure 8K).  Using this Ser-Ser-Lys substrate, both WT NRMT2 and NRMT2 
V224L were able to significantly lower the Km of NRMT1 (Figure 8L), further 
verifying the catalytic activity of NRMT2 is not needed, and indicating NRMT2 is 
not increasing NRMT1 activity via a substrate priming role, but by providing 









Figure 8. Catalytic activity of NRMT2 is not necessary for increased 
trimethylation by NRMT1. (A) Wildtype NRMT1 shows a Km of 1.1 µM when 
trimethylating the SPK-RCC1 peptide substrate, (B) while the Km of NRMT2 is 
55.6 µM. (C) The catalytically inactive NRMT2 V224L mutant is unable to 
methylate the same substrate. (D) Combing NRMT1 and NRMT2 lowers the Km 
of NRMT1 to 0.9 µM, while (E) the combination of NRMT1 and catalytically 
inactive NRMT2 V224L further lowers the Km of NRMT1 to 0.1 µM. (F) 
Comparison of Michaelis-Menton constants for NRMT1 alone, NRMT2 alone, or 
NRMT1 in combination with NRMT2 or NRMT2 V224L with SPK-RCC1 peptide 
as substrate.  Only the combination of NRMT1 with NRMT2 V224L was 
significantly different from NRMT1 alone.  Calculated constants are the mean of 
three independent experiments ± SEM.  *** denotes p< 0.001 as determined by 
unpaired Student’s t-test.  Using a less preferred, but still enzymatically-favorable 
substrate SSK-MYL9, (G) increases the Km of NRMT1 to 15.6 µM but shows no 
enzymatic activity with (H) NRMT2 or (I) NRMT2 V224L. (J) Combining NRMT1 
and NRMT2 decreases the Km of NRMT1 to 6.6 µM, and (K) the combination of 
NRMT1 and NRMT2 V224L further lowers the Km of NRMT1 to 4.4 µM. (L) 
Comparison of Michaelis-Menton constants for NRMT1 alone, NRMT2 alone, or 
NRMT1 in combination with NRMT2 or NRMT2 V224L with SSK-MYL9 peptide 
as substrate.  The constants for both the combinations of NRMT1 with NRMT2 
and NRMT1 with NRMT2 V224L were significantly different from NRMT1 alone.  
Calculated constants are the mean of three independent experiments ± SEM. * 
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and ** denote p<0.05 and 0.01, respectively, as determined by unpaired 




 To understand why NRMT2 V224L was able to significantly decrease the 
NRMT1 Km with the RCC1 peptide, and not WT NRMT2, I performed molecular 
modeling of the NRMT2 V224L mutant (Figure 9).  It is easy to see how V224L 
might disrupt NRMT2 catalytic activity, as Val224 is in the substrate binding 
pocket and is directly adjacent to Asn223, which forms critical hydrogen bonds 
and electrostatic interactions with substrate (Petkowski et al. 2013; Shields et al. 
2017).  When mutated to Leu, this residue extends much further into the pocket, 
potentially disrupting nearby interactions with substrate (Figure 9B).  
Interestingly, another residue critical for NRMT2 catalytic activity, Asp232 
(Petkowski et al. 2013), is also nearby in this pocket, and is one of the predicted 
secondary sites of interaction with NRMT1 (Figure 5C, Figure 9C).  Though they 
are not directly adjacent to each other they are connected by a short, 
unstructured loop, and it is possible to envision how a change in the position of 
residue 224 could indirectly affect the position of Asp232 (Figure 9C).  Mutation 
of Val224 to Leu could impact NRMT2 function via two different mechanisms, 
first by disrupting substrate binding and subsequent catalytic activity, and second 










Figure 9. A valine à leucine mutation at position 224 renders NRMT2 
catalytically inactive. (A) Cartoon rendering of NRMT2 monomer showing WT 
valine at position 224 (B, top) mutated to leucine (B, bottom) that eliminates 
methyltransferase activity. (C) Leu224 and Asp232 are connected by a short, 
unstructured loop. Images were produced in PyMOL.	 	
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NRMT2 overexpression cannot rescue NRMT1 knockout phenotypes 
The above data lead to a model where the NRMT1 homodimer normally 
functions alone as the primary N-terminal methyltransferase in cells, but can act 
synergistically with NRMT2 to increase N-terminal trimethylation levels at times 
of high need.  This model implies that NRMT2 is not simply a functionally 
redundant homolog of NRMT1 but an important activator.  To further confirm 
NRMT1 and NRMT2 are not functionally redundant, I wanted to test if NRMT2 
expression could rescue NRMT1 knockout phenotypes.  It has been shown that 
N-terminal dimethylation protects the N-terminus of cytochrome c557 from 
digestion in Crithidia oncopelti (Smith and Pettigrew 1980).  I wanted to see if N-
terminal mono- or trimethylation differentially affected this protection and affect 
the rate of decay, using a mammalian substrate with a known consensus 
sequence for both NRMT1 and NRMT2, the α isoform of SET (SETα) (Petkowski 
et al. 2012; Tooley et al. 2010). 
 Human SETα was C-terminally tagged with Dendra2 photoswitchable 
protein and lentivirally expressed in HCT116 human colorectal carcinoma cells at 
an MOI of 1 (Figure 10B).  Before excitation, Dendra2 fluoresces green, but 
when activated by UV-violet or blue light, fluoresces red (Figure 10A) (Zhang et 
al. 2007).  The red form is highly stable independently, but when fused to a 
protein of interest, its signal can be followed to determine the rate of decay of the 
protein (Zhang et al. 2007).  I first measured the rate of decay of SETα-Dendra2 
in control HCT116 cells (Figure 10C, blue).  I then showed the rate of decay of 
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SETα-Dendra2 in HCT116 NRMT1-/- cells was significantly quicker (Figure 10C, 
red). Overexpression of NRMT1 in the HCT116 NRMT1-/- cells restored the 
original rate of decay of SETα-Dendra2 (Figure 10C, green).  However, 
overexpression of NRMT2 in the HCT116 NRMT1-/- cells was not able to rescue 
the SETα-Dendra2 rate of decay, and it remained significantly different from the 
HCT116 control (Figure 10C, purple).  These data indicate N-terminal mono- and 
trimethylation are not functionally redundant and suggest that, unlike EZH1 and 
EZH2 (Shields et al., 2017), NRMT1 and NRMT2 are not serving the same 
function through different mechanisms.  Our data point to the stabilization of 
NRMT1 and an increase in substrate binding as important functions of NRMT2 
but do not rule out other specific roles for N-terminal monomethylation that are 









Figure 10.  NRMT2 overexpression cannot rescue NRMT1 knockout phenotypes 
(A) HCT116 NRMT1-/- cells transduced with empty pCDH virus (control), virus 
overexpressing NRMT1 (NRMT1 O/E), or virus overexpressing NRMT2 (NRMT2 
O/E) were also transduced with virus expressing SETα-Dendra2.  Pre conversion 
SETα-Dendra2 expresses in the GFP channel, post-conversion it expresses in 
the RFP channel. The RFP signal then decreases over time and a rate of decay 
can be calculated. (B) Western blots showing HCT116 cells express endogenous 
NRMT1 and were fully mono/dimethylated (me1/2RCC1) and trimethylated 
(me3RCC1) (lane 1).  In contrast, HCT116 NRMT1-/- cells do not express NRMT1 
or exhibit N-terminal trimethylation, but retain mono/dimethylation (lane 2). In 
HCT116 NRMT1-/- cells overexpressing NRMT1-FLAG, both NRMT1 protein and 
trimethylation were restored (lane 3). In HCT116 NRMT1-/- cells overexpressing 
NRMT2-FLAG, a slight increase in mono/dimethylation can be seen, with no 
restoration of NRMT1 or trimethylation (lane 4). FLAG blot shows both NRMT1-
FLAG and NRMT2-FLAG are expressing. Dendra2 blot shows SETα-Dendra2 
expression levels are similar between lines. GAPDH was used as a loading 
control.  (C) First, the rate of decay of SETα-Dendra2 was measured in control 
HCT116 cells (blue).  This rate of decay significantly increased in HCT116 
NRMT1-/- cells (red).  Overexpressing NRMT1-FLAG in HCT116 NRMT1-/- cells 
restores the original rate of decay (green), and there was no statistically 
significant difference between control and NRMT1 overexpression cell lines.  
Overexpressing NRMT2-FLAG in HCT116 NRMT1-/- cells cannot rescue the 
decay (purple), which remains significantly faster than control. Curves were 
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constructed by comparing loss of RFP signal over time as compared to time 0 
and are the mean of three independent experiments ± SEM. *, **, *** denotes 




Our work is the first to demonstrate a physical interaction between the N-terminal 
methyltransferase homologs, NRMT1 and NRMT2.  Here I show that NRMT1 
homodimers interact with NRMT2 monomers to form heterotrimers.  Heterotrimer 
formation increases the stability of NRMT1 but has no significant effect on the 
stability of NRMT2.  Though we have previously seen that co-expression with 
NRMT2 increases NRMT1 activity (Petkowski et al. 2013), I now show that 
NRMT2 catalytic activity is not necessary for this increase in NRMT1 activity and 
propose that NRMT2 is not priming for NRMT1, but instead increasing its 
stability.  I also show that N-terminal mono- and trimethylation are not functionally 
redundant, at least in regards to promoting protein stability, indicating that 
NRMT1 and NRMT2 are also not functionally redundant.  The sole role of 
NRMT2 may be to stabilize and activate NRMT1, or it may have other distinct 
functions.   
In addition to stabilizing METTL3, METTL14 has been proposed to 
enhance interaction with RNA substrates (Wang, Doxtader, and Nam 2016; 
Wang et al. 2016).  We have seen that NRMT1 has varying affinities for the 
different NRMT N-terminal consensus sequences (Petkowski et al. 2012), and it 
may be that binding of NRMT2 to the NRMT1 homodimer, strengthens its affinity 
for certain less favored consensus sequences.  Our in vitro methyltransferase 
data support this model, as NRMT2 binding had little effect on the Km of NRMT1 
when methylating a Ser-Pro-Lys peptide, but significantly decreased the Km of 
NRMT1 when methylating the less preferred Ser-Ser-Lys peptide.  We had 
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originally proposed that NRMT2 was a primer for NRMT1 that was expressed at 
times of high substrate burden (Petkowski et al. 2013), but it may be that NRMT2 
is expressed at times when less preferred substrates require methylation.  In this 
way, it is both providing stability to NRMT1 and altering its substrate preference. 
 These data indicate that, while overall unique, the interaction between 
NRMT1 and NRMT2 has the most in common with the interactions of PRMT1/3 
and METTL3/14.  Like PRMT1/3 and METTL3/14, binding of the homologs 
increases the stability of the active enzyme (Kafkova et al. 2017; Liu et al. 2014; 
Wang et al. 2014).  Similar to METTL14, but unlike PRMT3, NRMT2 has weak 
catalytic activity in vitro (Wang et al. 2014; Liu et al. 2014; Kafkova et al. 2017).  
However, SAM was visualized in the active site of the NRMT2 crystal, and I have 
seen that CRISPR-mediated knockout of NRMT1 results in a complete loss of N-
terminal trimethylation, but N-terminal monomethylation remains the same 
(Figure 8B) (Shields et al. 2017).  This indicates that, unlike METTL14, NRMT2 
also has some activity in vivo.  What the function of this in vivo N-terminal 
monomethylation is remains to be determined. 
 If charge or bulk of the N-terminus are the main regulatory aspects of N-
terminal PTMs, it seems intuitive that N-terminal monomethylation could not 
functionally replace trimethylation, as it is much smaller and does not produce a 
pH-independent positive charge (Stock et al. 1987).  However, similar to lysine 
monomethylation, N-terminal monomethylation could still have its own distinct 
function.  RNA polymerase II (Pol II) pausing is regulated by the switch between 
mono- and trimethylation of histone H4 lysine 20 (H4K20me1 and H4K20me3, 
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respectively) (Kapoor-Vazirani and Vertino 2014).  While H4K20me3 promotes 
pausing by inhibiting the recruitment of the male-specific lethal (MSL) complex, 
H4K20me1 recruits MSL and promotes the release of Pol II into elongation 
(Kapoor-Vazirani and Vertino 2014).  One way subtle changes in the degree of 
methylation can affect protein function so dramatically, is that each can be 
recognized by different methyl-reading chromodomains.  H4K20me1 can 
efficiently recruit the MSL complex to chromatin due to the chromo-barrel domain 
of MSL3 (Moore et al. 2010; Kim et al. 2010), whereas H4K20me3 is 
preferentially bound by the double tudor domain of the histone demethylase 
jumonji domain containing 2A (JMJD2A) (Garske, Craciun, and Denu 2008).  
Therefore, it is possible that N-terminal mono- and trimethylation could similarly 
recruit distinct proteins with different binding domains, and in doing so, 
differentially affect many cellular processes.  It will be interesting to determine if 
families of such N-terminal methylation “readers” exist.   
 Though the interactions between NRMT1 and NRMT2 seem the most 
distinct from the interactions between EZH1 and EZH2, there are also some 
similarities.  Most striking is the tissue distribution of the homologs.  NRMT1, like 
EZH1, is ubiquitously expressed in most adult tissue types (Petkowski et al. 
2013; Margueron et al. 2008). While NRMT2 has very low basal expression in 
adult mice, we do see enrichment in both skeletal muscle and the liver 
(Petkowski et al. 2013).  EZH2 also has very low basal expression in adult tissue, 
with some enrichment in the spleen, but seems to be highly expressed in the 
proliferative tissue of the kidney during development (Margueron et al. 2008).  It 
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has been hypothesized that these disparate expression patterns represent an 
evolutionary sub-functionalization of the homologs (Margueron et al. 2008).  
EZH1 is the general methyltransferase directly involved in transcriptional 
repression, while EZH2 is dedicated to placing repressive marks during 
replication (Margueron et al. 2008).  Though EZH1 and EZH2 are catalytically 
distinct, they are functionally redundant in regards to transcriptional repression, 
and their differential expression patterns could allow for a tighter regulation of this 
repression (Margueron et al. 2008).  The function of PRC2 complexes expressing 
both EZH1 and EZH2 remains to be determined (Margueron et al. 2008; Oliviero 
et al. 2016), but like PRMT1/3, METTL3/14, and NRMT1/2, co-expression might 
result in a more active complex, useful in times of high demand. 
Unlike EZH1/2, NRMT1 and NRMT2 do not seem to be functionally 
redundant.  Their evolution may have led to neo-functionalization instead of sub-
functionalization (Prince and Pickett 2002).  I propose a model where each has a 
distinct function, but at times when they are co-expressed, can form 
heterotrimers with increased N-terminal trimethylation activity.  In this way, 
regulated NRMT2 expression would serve to promote its developmental or cell 
type-specific role and increase N-terminal methylation when needed.  It will be 
interesting to see if NRMT2 expression is regulated during development or in 
proliferating tissues and continue to explore potential unique roles for N-terminal 
monomethylation. Also of note is the V224L NRMT2 mutation found in human 
breast cancer (Shields et al. 2017).  While NRMT1 has been shown to have 
cancer type-specific roles as a tumor suppressor or oncogene (Bonsignore, 
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Butler, et al. 2015; Shields et al. 2017), there is as yet no data demonstrating 
NRMT2 misregulation in any cancer type. Therefore, extensive characterization 
of this mutation has not occurred.  However, these data demonstrating it not only 
abolishes NRMT2 activity but also promotes NRMT1 activity make it an 
interesting candidate for a driver mutation in cancers that overexpress NRMT1 or 
a protective mutation in cancers that downregulate NRMT1.  Future studies will 
determine how expression of this mutant affects oncogenic phenotypes in such 
cancer cell lines. 
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CHAPTER III 




The work presented in Chapter II illustrates the physical interaction 
between the α-amino methyltransferase homologs, NRMT1 and NRMT2. I have 
demonstrated the formation of a heterotrimeric species, consisting of a 
homodimer of NRMT1 and monomer of NRMT2, which increases the stability of 
NRMT1 but does not impart a change of stability on NRMT2. Additionally, I have 
used in silico modeling to identify likely residues of interaction among the NRMT1 
homodimer, as well as the NRMT1-NRMT2 heterotrimer.  Functionally, I have 
shown that N-terminal trimethylation and monomethylation do not serve 
redundant purposes, with NRMT2 overexpression being unable to rescue the 
SETα stability phenotype associated with loss of NRMT1-associated 
trimethylation. Previous work indicated an increase in NRMT1-associated 
trimethylation when co-expressed with NRMT2 (Petkowski, 2013).  It was 
originally hypothesized that NRMT2 monomethylation was priming for NRMT1 
trimethylation.  However, I now show that NRMT2 catalytic activity is not needed 
for its promotion of NRMT1 activity, and propose NRMT2 increases NRMT1 
activity by stabilizing the enzyme. 
	 88	
Though NRMT2 activity is not needed for its activation of NRMT1, it does 
demonstrate weak in vitro and in vivo catalytic activity on its own (Petkowski et 
al.,2013).  Also, CRISPR-mediated loss of NRMT1, in vitro, abrogates the N-
terminal trimethylation of substrates but monomethylation of these same 
substrates is retained (Shields, 2017). This indicates that providing stability to 
NRMT1 may not be the sole purpose of NRMT2.  The following chapter will 
discuss potential unique roles of N-terminal monomethylation, how they could be 
experimentally determined, and how currently unstudied mutations in NRMT2 
could actually be important on their own right or through their impact on NRMT1. 
 
Monomethylation vs. Trimethylation 
 Yeast Set1 is a member of the COMPASS complex and was the first 
identified methylase capable of mono-, di-, and trimethylation of lysine 4 of 
histone 3 (H3K4) (Briggs et al., 2001; Krogan et al., 2001; Schneider et al., 
2005). Drosophila contain three H3K4 methyltransferases related to Set1 and 
found in COMPASS complexes- dSet1, Trx, and Trithorax-related (Trr), whereas 
mammals possess two representatives for each of the H3K4 methyltransferases 
found in drosophila (Mohan et al., 2011; Silatifard 2012). The Set1 orthologues in 
both drosophila and mammals are responsible for the bulk of all levels of 
methylation of H3K4, and these levels are tightly controlled during different 
stages of development (Mohan et al., 2011; Sedkov et al., 2003; Chauhan et al., 
2012). Active promoter regions are marked by H3K4 trimethylation (H3K4me3), 
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whereas promotor-distant enhancer regions are specifically marked by H3K4 
monomethylation (H3K4me1) (Heintzman et al., 2007). These methylation states 
of enhancers are also noted to distinguish active (noted by H3K4me1 and H3K27 
acetylation) versus inactive states (noted by H3K4me1 and H3K4me3) 
(Heintzman et al., 2009).  
The COMPASS complex localizes to both promoters and enhancers, and 
the Trr methyltransferase (mammalian homolog: MII3) is required for the 
maintenance of H3K4me1, with significant loss of H3K4me1 and increase in 
H3K27me3 noted upon knockdown of this Trr or MII3. The loss of H3K4me1 and 
increase in H3K27me3 switches the enhancer from an inactive to active state 
(Herz, 2012). Should this switch from an inactive to active state occur in 
oncogenes, it’s possible the misregulation of monomethylation could have 
pathological consequences. In a similar manner, the deposition of H3K4me1 by 
mammalian MLL3/4 at enhancers is shown to correlate with increased levels of 
chromatin interaction and gene activity during differentiation. Loss of H3K4me1 
reduces these long-range interactions between promoters and enhancers and 
subsequently causes defects during development (Yan et al., 2018).  
Similar to the enzymatic action catalyzed by NRMT2, protein arginine 
methyltransferase-7 (PRMT7) is unique in that it is only capable of 
monomethylating its target proteins (Cáceres et al., 2018). Each level of 
methylation on arginine residues of histones can have distinct functional 
consequences. For example, dimethylation of arginine 2 on histone H3 
(H3R2me2) inhibits the Set1-mediated trimethylation of H3K4, maintaining 
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transcriptional silencing. However, monomethylation of this same residue 
(H3R2me1) does not induce Set1 inhibition and its associated H3K4 
trimethylation and is associated with active transcription (Kirmizis et al., 2009). 
PRMT7, like NRMT2, is also found less broadly expressed than other PRMT 
family members, and its highest expression is in skeletal muscle (Jeong et al., 
2016). It is also notably found in mouse embryonic stem cells and is thought to 
regulate pluripotency and differentiation. (Buhr et al., 2008).  
PRMT7-null mice show reduced oxidative metabolism and increased age-
related obesity, indicating a distinct functional role of monomethylation in skeletal 
muscle metabolism (Jeong et al., 2016).  In another function, similar to that of the 
NRMT family, PRMT7 and its associated monomethylation activity are 
associated with genes associated with DNA damage repair (Karkhanis et al., 
2012).  PRMT7 contains an arginine binding pocket featuring larger residues 
than those found in other PRMT family members capable of dimethylation. The 
steric hindrance conveyed by these bulkier residues contributes to the 
monomethylation-only catalytic activity of PRMT7 (Jain et al., 2016; Cáceres et 
al., 2018). Interestingly, mutation of one particular active site residue, Glu181 to 
aspartate increases the size of the active site and corresponding affinity for 
monomethylated substrates, ultimately changing PRMT7 from a 
methyltransferase only capable of monomethylation to one capable of mono-, 
and dimethylating substrates (Debler et al., 2016).  
Sequence alignment of PRMT7 and its PRMT homologs capable of 
dimethylation yield fewer regions of conservation compared to NRMT1 and 
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NRMT2, which share a 50% sequence identity and 75% sequence similarity, with 
all the catalytic residues being fully conserved (Cáceres et al., 2018; Petkowski 
et al., 2013). The distinct feature of NRMT2, setting it apart from NRMT1, is the 
additional 60 amino acid N-terminal tail, comprised of two alpha helices. This tail 
is unstructured and floats freely from the N-terminal region of the enzyme, and it 
was initially thought that this bulky region was likely responsible for the detection 
of previously methylated substrates, thus restricting NRMT2 to monomethylation 
only (Petkowski et al., 2013). Additionally, while the catalytic regions of NRMT1 
and NRMT2 are similar in structure, they differ in residues. It was hypothesized 
that switching the catalytic residues of NRMT2 to those of NRMT1 could yield di- 
and trimethylating capability for NRMT2 (Petkowski et al., 2013).  We have 
conducted these experiments and found the removal of the N-terminal tail does 
not change the monomethylation capacity of NRMT2 to one of di- or 
trimethylation, but abolishes activity of NRMT2 altogether (Shields et al., 2017). 
Addition of the tail to NRMT1, failed to yield soluble recombinant protein (Shields 
et al., 2017).  Furthermore, mutation of the catalytic residues of NRMT2 to those 
of NRMT1 also yielded no change in catalytic ability or altered substrate 
specificity (Shields et al., 2017).  
I have now shown that while NRMT2 does have enzymatic function on its 
own, one of its major roles is contributing to the structural stability of NRMT1. It is 
likely the additional 60 amino acid tail is playing a structurally supportive versus 
catalytic role in the heterotrimer complex. A number of studies have 
demonstrated disruptions to unstructured regions of proteins distant from the 
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active site can have functional consequences and/or affect protein stability 
(Bromberg & Rost, 2009; Teng et al., 2010; Yang et al., 2013). At high 
concentrations, proteins with intrinsically disordered regions often bind to multiple 
partners with modest affinity, as the mass action caused by this high 
concentration overcomes the specificity of interaction (Vavouri et al., 2009). 
These unfavorable interactions explain the toxicity found by the overexpression 
of these proteins in some disease states. It is possible the highly flexible and 
dynamically plastic N-terminal tail of NRMT2 is cause for its tightly controlled, 
and thus overall low expression throughout tissues. Many proteins that contain 
intrinsically disordered regions are able to bind a broad range of partners, 
including other proteins, nucleic acid structures, or even themselves (He et al., 
2009). I have shown that removal of the unstructured tail of NRMT2 abolishes its 
ability to monomethylate target peptides in vitro, and this loss of specificity could 
be attributed to the decreased protein-protein interaction previously conveyed by 
the N-terminal tail (discussed in Shields et al., 2017). 
 
Potential Roles for N-terminal Monomethylation 
 
I have shown here that stability of the NRMT1 target SETα is significantly 
decreased upon knockout of NRMT1 compared to control cells (Figure 10 A & 
C). This phenotype can be rescued by overexpression of NRMT1 alone, but not 
NRMT2 (Figure 10 A & C). These data indicate that, in regards to regulating 
protein stability, N-terminal methylation is not functionally redundant with N-
terminal trimethylation.  This could be due to its smaller size or its inability to 
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produce a positively charged N-terminus.  However, in addition to regulating 
protein stability, N-terminal trimethylation also regulates protein-DNA interactions 
and is predicted to regulate protein-protein interactions (Tooley et al., 2010; Chen 
et al., 2007).  N-terminal monomethylation could function redundantly in either of 
these roles. 
We have previously seen that loss of NRMT1 leads to increased migration 
of MCF-7 cells (Bonsignore, 2015).  To test if this migration phenotype, can be 
rescued by restoration of just N-terminal monomethylation, I repeated the cell 
migration assay using control MCF-7 cells, NRMT1-knockdown MCF-7 cells 
(transduced with an shRNA against NRMT1), and NRMT1-knockdown MCF-7 
cells rescued with flag-tagged NRMT1 or NRMT2, respectfully. (Figure 11A). 
Cells were grown to ~70% confluency and scratched with a pipette tip and 
images were taken at 0, 24, 48, and 72 hours (Figure 11B). As expected, NRMT1 
knockdown in MCF-7 cells increased the migratory ability of the cells over that of 
control. Interestingly, at the 48 and 72-hour time-points, rescue of this migration 
phenotype is accomplished by both NRMT1 and NRMT2 (Figure 11C).  This 
indicates that while N-terminal monomethylation is not functionally redundant in 
regards to regulating protein stability, it can functionally replace N-terminal 
trimethylation when promoting migration.  I propose that in this particular 









Figure 11. NRMT1 knockdown increases migratory potential of MCF-7 breast 
adenocarcinoma cells. (A) Representative immunoblots showing control MCF-7 
lysate (lane 1), NRMT1 knockdown (lane 2), NRMT1 knockdown + flagged-
tagged NRMT1 rescue construct (lane3), NRMT1 knockdown + flagged-tagged 
NRMT2 rescue construct (lane 4). (B) 24, 48, 72-hour time points measuring 
distanced moved relative to 0 hour. (C) Representative images from each cell 
line at each time point. Distance moved was determined by measuring total area 
of no cell invasion in three wells per experiment per day. Values are a 
combination of three independent experiments and error bars represent SEM. 
GraphPad Prism was used to determine statistical significance via two-way 
ANOVA between groups followed by a multiple comparisons test via Tukey’s 




One NRMT1 target, myosin light chain-9 (MYL9), plays a regulatory role in 
the actin-myosin II complex and is promotes cytoskeletal dynamics and motion in 
both muscle and non-muscle cells (Ouderkirk & Krendal, 2014). MYL9 has also 
been implicated in cytoskeletal rearrangement and both overexpression and 
aberrant activation of MYL9 can promote invasion of cancer-associated 
fibroblasts and increased metastatic potential of primary carcinoma cells (Calvo 
et al., 2013; Cermák et al., 2010).  We have seen that loss of N-terminal 
methylation of MYL9 promotes both cell spreading and cell migration (Nevitt, 
unpublished data), and I attribute the increased migration of MCF7 cells seen 
with NRMT1 knockdown, at least in part, to altered action of MYL9. 
 Our lab has recent SILAC mass spectrometry data showing that mono-, 
and trimethylation of MYL9 both block a significant portion of its protein-protein 
interactions (Nevitt, unpublished data), and I propose that N-terminal methylation 
of MYL9 disrupts protein-protein interactions that inhibit the migratory functions of 
MYL9. Rescue by NRMT2 allows only monomethylation to occur, but this is 
adequate to block aberrant protein-protein interactions and return cells to a less 
migratory phenotype.  
The third function of N-terminal trimethylation is to regulate protein-DNA 
interactions (Chen et al., 2007).  I predict that N-terminal monomethylation will 
not be able to rescue this function, as only trimethylation produces a pH-
independent charge on the N-terminal residue, facilitating interaction with the 
negatively charged phosphate backbone of DNA.  However, to test this 
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hypothesis, one could look at the DNA binding ability of mono- vs trimethylated 
MYL9.  We have previously used chromatin immunoprecipitation (ChIP) to show 
loss of N-terminal methylation reduces the occupancy of MYL9 at the ICAM1 
promoter (Nevitt, unpublished data).  To see if the level of methylation is 
important for this promoter occupancy, these experiments can be performed in 
the HCT116 CRISPR/Cas9 NRMT1 knockout strain rescued with NRMT1 or 
NRMT2. I hypothesis that restored binding capacity of MYL9 to the ICAM1 
promoter will only be seen after NRMT1 rescue, due to the potential for 
trimethylation and a pH-independent positive charge on the N-terminus of MYL9.  
 
 
NRMT2 mutations in human cancers 
 
In testing whether NRMT2 catalytic activity was needed to activate 
NRMT1, I discovered that the V224L NRMT2-null mutant found in human breast 
cancer actually activated NRMT1 better than wild type NRMT2 (Figure 7E & K). 
Molecular modeling showed that mutation of Val224 to Leu could impact NRMT2 
function via two different mechanisms, first by disrupting substrate binding and 
subsequent catalytic activity, and second by promoting Asp232 accessibility and 
subsequent complex formation with NRMT1 (Figure 9). To date, ninety-one 
NRMT2 missense mutations have been identified in human cancers (Cosmic 
Catalogue of Somatic Mutations in Cancer), and I decided to see if any additional 
mutations could predictably alter NRMT1/NRMT2 interactions.  
Of the 91 mutations, a number affect residues I have found to be 
implicated in formation of the NRMT1-NRMT2 heterotrimer (bold, Table I), while 
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others are found in the active site of NRMT2 near conserved aromatic residues 
(Petkowski et al., 2013). As noted in Chapter II, modeling predicts that 
heterotrimer formation of the NRMT1 dimer and NRMT2 monomer is governed, 
in part, by non-covalent interactions between proximally located resides (Figure 
4).  Of the seven missense mutations found in human cancers listed in Table I, 
four affect specific residues deemed important for heterotrimer formation (Figure 
5F), and modeling predicts each one of these increases the distance between 
the wildtype NRMT1 and NRMT2 residues (Figures 12A,C-15A,C) and mutated 
residues (Figures 12B,D-15B,D). This increase in distance will likely disrupt these 
non-covalent forces associated with heterotrimer formation, possibly destabilizing 
the structure.   
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Table I 
Mutation Primary Tissue 
Q67H Lung 










Table I: NRMT2 missense mutations found in human cancers. Bolded mutations 









& WT NRMT1 
residues (Å) 
Gln67His Ser44 2.1 5.1 
Phe68Leu Ser39 1.0 2.5 
Arg71Thr Gln50 1.4 10.6 
Asp232Asn Pro83 3.2 5.3 





Table II. NRMT2 mutations increase distance between corresponding NRMT1 








Figure 12. NRMT2 mutations found in cancers. (A) WT NRMT2 possessing 
glutamine at residue 67 (blue). (B) Q67H mutation (blue) found in lung cancer. 
(C) Bond length (Å) between NRMT2 D67 and WT NRMT1 S44. (D) The 
distance measured in (C) is increased to 5.1 Å in the NRMT2 Q67H mutant.  
Mutational analysis and molecular measurements were produced using the 
PyMOL Molecular Graphics System, Version 2.0.6 (Schrödinger, LLC). PDB 









Figure 13. NRMT2 mutations found in cancers. (A) WT NRMT2 possessing 
phenylalanine at residue 68 (blue). (B) F68L (blue) found in pancreatic cancer. 
(C) Bond length (Å) between NRMT2 F68 and WT NRMT1 S39. (D) The distance 
measured in (C) is increased to 2.5 Å in the NRMT2 F68L mutant.  Mutational 
analysis and molecular measurements were produced using the PyMOL 
Molecular Graphics System, Version 2.0.6 (Schrödinger, LLC). PDB accession 







Figure 14. NRMT2 mutations found in cancers. (A) WT NRMT2 possessing 
arginine at residue 71 (blue). (B) R71T (blue) found in pancreatic cancer. (C) 
Bond length (Å) between NRMT2 R71 and WT NRMT1 Q50. (D) The distance 
measured in (C) is increased to 10.6 Å in the NRMT2 R71T mutant.  Mutational 
analysis and molecular measurements were produced using the PyMOL 
Molecular Graphics System, Version 2.0.6 (Schrödinger, LLC). PDB accession 







Figure 15. NRMT2 mutations found in cancers. (A) WT NRMT2 possessing 
aspartic acid at residue 232 (blue). (B) D232N mutation (blue) found in prostate 
cancer. (C) Bond length (Å) between NRMT2 D232 and WT NRMT1 P83. (D) 
The distance measured in (C) is increased to 5.3 Å in the NRMT2 D232N mutant.  
Mutational analysis and molecular measurements were produced using the 
PyMOL Molecular Graphics System, Version 2.0.6 (Schrödinger, LLC). PDB 















Missense mutations, including those outside the active site, have been 
widely implicated in the alteration of protein structure and stability (Ode et al., 
2007; Lorch et al., 2000; De Cristofaro et al., 2006). Changes of residues, 
especially those altering polarity or charge, can direct conformational changes in 
the native folding of the protein. These include disruption of salt bridges and 
hydrogen bonds, which facilitate potential interactome alterations. Additionally, 
single aberrant amino acid substitutions have been shown to disrupt protein-
protein interactions and substrate binding. Ung et al have shown a Glu230 to Gln 
mutation in the cAMP-dependent protein kinase catalytic subunit leaves the 
enzyme with physical properties similar to that of the wildtype, but with the 
inability to form a native ternary complex with MgATP and a protein kinase 
inhibitor (Ung et al., 2006). Protein function alteration may direct or as a result of 
an alteration of protein stability conveyed by a missense mutation. Of the number 
of known disease-causing missense mutations, 83% result in a change of protein 
stability (Wang & Moult, 2001).   
I have shown that NRMT1 is structurally dependent upon the presence of 
NRMT2 to avoid premature degradation (Figure 7). The aforementioned NRMT2 
mutations found in human cancers all decrease the proximity of key interacting 
residues I predict stabilize the NRMT1/NRMT2 complex. With this decrease in 
stability, likely comes an increase in protein degradation. If the heterotrimer 
complex is degrading prematurely, it’s unlikely that key substrates are being 
properly trimethylated. As noted, N-terminal trimethylation produces a pH-
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independent positive charge on substrates and functions to increase interaction 
with the positively-charged substrates and negatively-charged phosphate 
backbone of DNA. The inability of substrates to be trimethylated, facilitated by 
the early degradation of the NRMT heterotrimer, could cause misregulation of 
key protein-protein or protein-DNA interactions implicated in the suppression of 
tumorigenesis, thus acting as a driver mutation for these small subsets of 
cancers. This would be relatively straightforward to examine experimentally, 
although a full NRMT2 knockout cell line would need to be initially developed. A 
number of mutagenesis experiments could be carried out to produce the Q67H, 
F68L, R71T, and D232N NRMT2 mutants. These could be co-expressed, along 
with WT NRMT1 in a NRMT2-null cell line and NRMT1 stability could be 
measured via cycloheximide, similar to Figure 6 in Chapter II.  
Computational molecular mapping of disease causing mutations onto 
known protein structures and free energy perturbation (FEP) calculation are 
additional in silico methods of determining structurally and functionally important 
sites and the effects of mutations on protein stability (Dimmic et al., 2005; Dixit et 
al., 2009).  FEP takes into account the energies between covalently bonded 
atoms, as well as the geometry and torsion forces between WT and mutated 
residues in comparison to their surrounding environment to deduce a comparable 
value of electrostatic energy and subsequent stability on the entire molecule 
(Dixit et al., 2009). While these techniques are processor-heavy and require a 
robust learning curve, they are able to generate large amounts of data that can 
subsequently be used to develop hypotheses and direct further bench work.  
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The COSMIC database also lists three NRMT2 missense mutations found 
in residues not previously implicated in the heterotrimer stability. One of these, 
S131N, slightly increases the size of the SAM-binding pocket, near which the WT 
serine is positioned. This marginal increase in size of the SAM-binding motif 
could have detrimental functional consequences on an enzyme that already has 
very select and relatively low catalytic abilities. The inability of NRMT2 to stabilize 
SAM and thus utilize it for monomethylation will be of key interest as the tissue- 
and developmentally-specific roles of monomethylation are deduced.  
Interestingly, the two other missense mutations listed on the COSMIC 
database, T17A and L57S, are located on the 60 amino acid, free N-terminal tail 
of the enzyme. As noted in the previous chapters, this tail is the most distinct 
feature of NRMT2 when compared to NRMT1, and floats freely from the N-
terminal end (as such, it does not readily crystalize and is missing from PDB 
accession 5UBB) (Petkowski et al., 2013). We have shown that removal of the N-
terminal tail abolishes all methylation activity of NRMT2 (discussed in Shields et 
al., 2017).  It seems unlikely that the tail functions in NRMT1/NRMT2 
trimerization, as my co-immunoprecipitation data show its inclusion seems to 
disrupt binding (Figure 6). Similar to what was described above, experiments on 
protein stability and heterotrimer formation in the presence of WT NRMT1 and 
tailless NRMT2 could provide some insight into this phenomenon.  
NRMT1 and NRMT2 share a general consensus sequences for 
substrates, but I have shown there are some distinct differences (Figure 8), and it 
is possible this tail regulates these differences.  The NRMT2 V224L mutant has 
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no methyltransferase activity of its own. However, when combined in vitro with 
NRMT1, it reduces the KM of binding the SPK-RCC1 peptide around 10-fold 
versus NRMT1 alone, and around 7-fold versus the combination of NRMT1 and 
WT NRMT2. An additional significant outcome, though less pronounced, is seen 
when binding the SSK-MYL9 peptide. Though the V224L mutation is not in the N-
terminal tail, it is possible the T17A and L57S mutations are increasing or 
decreasing substrate-binding efficiency in a similar manner. Similar in vitro 
methyltransferase experiments using recombinantly-produced NRMT2 T17A and 
NRMT2 L57S, alone and combined with WT NRMT1, would give evidence into 
any changes in binding efficiency conveyed by these mutations. It is also 
possible that the N-terminal tail is indeed cause for increasing the binding affinity 
of NRMT2 for particular substrates. Experiments using circular dichroism or 
isothermal calorimetry would yield information on binding and dissociation of 
Wildtype, as well as mutant NRMT2, with and without the presence of NRMT1, 
on any number of selected substrates.  
In my initial model, I predicted that the behavior of NRMT1 and NRMT2 
would be similar to that of the class I methyltransferases METTL3 and METTL14 
(Liu, 2014), where a heterodimeric complex would form with the less catalytically 
active NRMT2 promoting N-terminal trimethylation via NRMT1 (see Figure 1). 
Experimentally, I have demonstrated that while NRMT1 and NRMT2 do 
physically interact, they do so as a heterotrimeric species consisting of a NRMT1 
dimer and NRMT2 monomer. Furthermore, I have shown that NRMT1 and 
NRMT2, individually, have catalytic activity. However, the catalytic activity of 
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NRMT2 is not necessary for the increased trimethylation by NRMT1. Instead, I 
have shown the promotion of N-terminal trimethylation to be dependent on the 










Figure 16. Revised model of NRMT1 and NRMT2 interaction. A NRMT1 
homodimer and NRMT2 monomer physically interact to promote stability and N-
terminal trimethylation.  
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 The methyltransferome, like other post-translational modifications, adds 
yet another layer of diversity beyond the central dogma of molecular biology. The 
many facets of “readers,” “writers,” and “erasers” of methylation will continue to 
be deduced and only more-so as the combination of computational chemistry, 
structural biology, and biochemistry gets ever more advanced. The work 
presented in this dissertation is but a small, albeit integral, part of vast landscape 
of chemical modifications to macromolecules that no doubt has an impact on 
health and disease. As the experiments proposed in chapter III are completed, 
the impact N-terminal methylation has on development, physiology, and the 
promotion or suppression of pathogenic cell growth will become more 
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